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Abstract: Determining the cause of stroke does influence choices for management. categorization of subtypes of ischemic stroke has 
had considerable study, but definitions are hard to formulate and their application for diagnosis in an individual patient is often problem-
atic. Cerebral ischemia initiates a complex cascade of events at genomic, molecular, and cellular levels, and inflammation is important in 
this cascade. In 1993 for For the Trial of Org 10172 in Acute Stroke Treatment (TOAST), Adams et al] conducted a placebo-controlled, 
randomized, blinded study of the low-molecular-weight heparinoid given to patients within 24 hours after stroke and developed a system 
for diagnosis of subtype of ischemic stroke that uses components of existing diagnostic schemes. The type of acute ischemic stroke was 
classified according to the TOAST classification: 1) Large Artery AtheroSclerosis (LAAS); 2) CardioEmbolic Infarct (CEI); 3) LACunar 
infarct (LAC); 4) stroke of Other Determined Etiology (ODE); 5) stroke of UnDetermined Etiology (UDE) (see Fig. (1)). On the basis of 
pathophysiologic differences of each stroke subtype it’s possible to hypothesize a different pattern of immuno-inflammatory activation in 
relation of ischemic stroke subtype. A nonspecific systemic inflammatory response occurs after both ischemic and hemorrhagic stroke, 
either as part of the process of brain damage or in response to complications such as deep venous thrombosis. Several studies have re-
ported that higher levels of inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are associated with worse 
outcome after ischemic stroke.  
Our group reported that patients with cardioembolic subtype showed significantly higher median plasma levels of TNF-, IL-6, IL-1 
whereas the lacunar subtype showed significantly lower median plasma levels of TNF-, IL-6 and IL-1. Our findings underlined the 
significant association was noted between the severity of neurological deficit at admission, the diagnostic subtype and some inflamma-
tory variables.  
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INTRODUCTION 
 The two broad categories of stroke, hemorrhage and ischemia, 
are diametrically opposite conditions: hemorrhage is characterized 
by too much blood within the closed cranial cavity, while ischemia 
is characterized by too little blood to supply an adequate amount of 
oxygen and nutrients to a part of the brain [1]. Each of these catego-
ries can be divided into subtypes that have somewhat different 
causes, clinical pictures, clinical courses, outcomes, and treatment 
strategies. As an example, intracranial hemorrhage can be caused 
by intracerebral hemorrhage (ICH), also called parenchymal hemor-
rhage, which involves bleeding directly into brain tissue, and suba-
rachnoid hemorrhage (SAH), which involves bleeding into the 
cerebrospinal fluid that surrounds the brain and spinal cord.  
 Stroke subtyping can have different purposes, e.g. describing 
patients’ characteristics in a clinical trial, grouping patients in an 
epidemiological study, careful phenotyping of patients in a genetic 
study, and classifying patients for therapeutic decision-making in 
daily practice. The classification should distinguish between 
ischemic and hemorrhagic stroke, subarachnoid hemorrhage, cere-
bral venous thrombosis, and spinal cord stroke. Regarding the 4 
main categories of etiologies of ischemic stroke (i. e. atherothrom-
botic, small vessel disease, cardioembolic, and other causes), the 
classification should reflect the most likely etiology without ne-
glecting the vascular conditions that are also found (e. g. evidence 
of small vessel disease in the presence of severe large vessel ob-
structions). Phenotypes of large cohorts can also be characterized 
by surrogate markers or intermediate phenotypes (e.g. presence of 
internal carotid artery plaque, intima-media thickness of the com- 
mon carotid artery, leukoaraiosis, microbleeds, or multiple lacu-
nae). Parallel classifications (i. e. surrogate markers) may serve 
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as within-study abnormalities to support research findings. Our 
group reported  
 Until recently, observational epidemiological studies of stroke 
were based mainly on pathological types of stroke. Many of these 
studies, which adopted near “ideal” methods, 5-17 had, in general, 
limited access to both the clinical expertise and the technologies 
(eg, carotid ultrasound, CT or MR imaging, and echocardiography) 
to perform a valid etiologic subtype classification. Increasingly, 
epidemiology is following clinical practice and not only considers 
all strokes together as the necessary first step but divides them into 
the 3 pathological types and then into various subtypes as well.  
 Determining the cause of stroke does influence choices for 
management. ategorization of subtypes of ischemic stroke has had 
considerable study, but definitions are hard to formulate and their 
application for diagnosis in an individual patient is often problem-
atic. In the past, classifications have been based primarily on risk 
factor profiles, clinical features of the stroke, and the findings on 
brain imaging studies Yet, clinical and brain imaging features over-
lap and are not specific for any particular subtype of ischemic 
stroke.  
 Cerebral ischemia initiates a complex cascade of events at ge-
nomic, molecular, and cellular levels, and inflammation is impor-
tant in this cascade, both in the Central Nervous System (CNS) and 
in the periphery. The entire spectrum of inflammatory processes is 
likely to act in concert in stroke but cytokines are important media-
tors of stroke-induced immunological/inflammatory reaction which 
contributes to brain infarct progression as well as to the disease 
severity and outcome.  
 On the basis of pathophysiologic differences of each stroke 
subtype it’s possible to hypothesize a different pattern of immuno-
inflammatory activation in relation of ischemic stroke subtype.  
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ISCHEMIC STROKE SUBTYPES 
 Until recently, observational epidemiological studies of stroke 
were based mainly on pathological types of stroke. Many of these 
studies, which adopted near “ideal” methods, [2, 8] had, in general, 
limited access to both the clinical expertise and the technologies 
(eg, carotid ultrasound, CT or MR imaging, and echocardiography) 
to perform a valid etiologic subtype classification. Increasingly, 
epidemiology is following clinical practice and not only considers 
all strokes together as the necessary first step but divides them into 
the 3 pathological types and then into various subtypes as well.  
 Categorization of subtypes of ischemic stroke has had consider-
able study, but definitions are hard to formulate and their applica-
tion for diagnosis in an individual patient is often problematic. In 
the past, classifications have been based primarily on risk factor 
profiles, clinical features of the stroke, and the findings on brain 
imaging studies (computed tomography [CT] or magnetic reso-
nance imaging [MRI]). Yet, clinical and brain imaging features 
overlap and are not specific for any particular subtype of ischemic 
stroke.  
 Bamford et a1. [9] recently reported that outcomes and likeli-
hood of recurrent stroke differed markedly by stroke subtype; large 
hemispheric infarcts, usually resulting from occlusion of the inter-
nal carotid artery or proximal middle cerebral artery, had the worst 
prognosis.  
 These investigators classified the strokes based on clinical fea-
tures that forecasted the size and site of the ischemic lesion, but 
they did not consider the potential etiology of the stroke. Other 
investigators have noted that the etiology of stroke does influence 
prognosis. Sacco et a1. [10] noted that mortality was higher among 
patients with large-artery atherosclerotic lesions than among pa-
tients with lacunes. Recurrent strokes are more likely among pa-
tients with cardioembolic stroke than among patients with stroke of 
other causes [11, 12]. The 1-month mortality after cardioembolic 
stroke is also higher than that with strokes of other etiologies [13, 
14].  
 In 1993 for For the Trial of Org 10172 in Acute Stroke Treat-
ment (TOAST), Adams et al [15] conducted a placebo-controlled, 
randomized, blinded study of the low-molecular-weight heparinoid 
given to patients within 24 hours after stroke and developed a sys-
tem for diagnosis of subtype of ischemic stroke that uses compo-
nents of existing diagnostic schemes. The type of acute ischemic 
stroke was classified according to the TOAST classification: 1) 
Large Artery AtheroSclerosis (LAAS); 2) CardioEmbolic Infarct 
(CEI); 3) LACunar infarct (LAC); 4) stroke of Other Determined 
Etiology (ODE); 5) stroke of UnDetermined Etiology (UDE) [see 
Fig. (1)].  
 Large Artery AtheroSclerosis (LAAS): These patients will have 
clinical and brain imaging findings of either significant (>50%) 
stenosis or occlusion of a major brain artery or branch cortical ar-
tery, presumably due to atherosclerosis. Clinical findings include 
those of cerebral cortical impairment (aphasia, neglect, restricted 
motor involvement, etc. ) or brain stem or cerebellar dysfunction. 
Cortical or cerebellar lesions and brain stem or subcortical hemi-
spheric infarcts greater than 1. 5 cm in diameter on CT or MRI are 
considered to be of potential large-artery atherosclerotic origin. 
Supportive evidence by duplex imaging or arteriography of a steno-
sis of greater than 50% of an appropriate intracranial or extracranial 
artery is needed. Diagnostic studies should exclude potential 
sources of cardiogenic embolism.  
CardioEmbolic Infarcts (CEI)  
 This category includes patients with arterial occlusions pre-
sumably due to an embolus arising in the heart. Cardiac sources are 
divided into high-risk and medium-risk groups based on the evi-
dence of their relative propensities for embolism. At least one car-
diac source for an embolus must be identified for a possible or 
probable diagnosis of cardioembolic stroke. Clinical and brain im-
aging findings are similar to those described for large-artery athero-
sclerosis. Evidence of a previous TIA or stroke in more than one 
vascular territory or systemic embolism supports a clinical diagno-
sis of cardiogenic stroke. Potential large-artery atherosclerotic 
sources of thrombosis or embolism should be eliminated. A stroke 
in a patient with a medium-risk cardiac source of embolism and no 
other cause of stroke is classified as a possible cardioembolic 
stroke.  
LACunar Infarct (LAC) 
 The patient should have one of the traditional clinical lacunar 
syndromes and should not have evidence of cerebral cortical dys-
function. A history of diabetes mellitus or hypertension supports the 
clinical diagnosis. The patient should also have a normal CT/MRI 
examination or a relevant brain stem or subcortical hemispheric 
lesion with a diameter of less than 1. 5 cm demonstrated.  
 Stroke of Other Determined Etiology (ODE): This category 
includes patients with rare causes of stroke, such as non-athero-
sclerotic vasculopathies, hypercoagulable states, or hematologic 
disorders. Patients in this group should have clinical and CT or 
MRI findings of an acute ischemic stroke, regardless of the size or 
location. Diagnostic studies such as blood tests or arteriography 
should reveal one of these unusual causes of stroke. Cardiac sources 
of embolism and large-artery atherosclerosis should be excluded by 
other studies.  
Stroke of UnDetermined Etiology (UDE) 
 In several instances, the cause of a stroke cannot be determined 
with any degree of confidence. Some patients will have no likely 
etiology determined despite an extensive evaluation. In others, no 
cause is found but the evaluation was cursory.  
Because most etiologic diagnoses in stroke are not based on patho-
logical confirmation and are thus presumptive, investigators are 
allowed to express their certainty by classifying the likelihood of 
diagnosis as probable or possible. This is an important attribute of 
the TOAST classification system because it permits more careful 
scrutiny of those cases in whomthe diagnosis is uncertain and may 
help any adjudication process. Any categorization of subtypes of 
ischemic stroke contains some mixture of patients with similar but 
not identical brain injuries or vascular pathologies. It also includes 
some degree of inflexibility, a feature that is in common with any 
system of grouping patients; for example, a physician cannot diag-
nose cardioembolism in a patient who has a suggestive history 
when the diagnostic studies do not substantiate the presence of 
heart disease.  
 Based on the experiences of several large singlecenter or multi-
center demographic studies, the most common causes of stroke are 
large-artery atherosclerosis, cardioembolism, and small-artery oc-
clusion [16, 17]. Because these are the three largest groupings of 
ischemic stroke and because the prognoses of patients in these divi-
sions differ, examining responses to acute treatment in these groups 
is clinically important.  
 On the basis of TOAST classification Kolominsky-Rabas [18] 
conducted a study to determine the incidence, recurrence, and long-
term survival rates of ischemic stroke subtypes by a mechanism-
based classification scheme (Trial of ORG 10172 in Acute Stroke 
Treatment, or TOAST). Authors identified all 583 residents of the 
city of Erlangen, Bavaria, Germany, with a first ischemic stroke 
between 1994 and 1998. Multiple overlapping sources of informa-
tion were used to ensure completeness of case ascertainment. The 
cause of ischemic stroke was classified according to the TOAST 
criteria. Patients were followed up at 3 months and 1 and 2 years 
after stroke onset. In this study The age-standardized incidence 
rates for the European population (per 100 000) regarding ischemic 
stroke subtypes were as follows: cardioembolism, 30. 2 (95% CI 
25. 6 to 35. 7); small-artery occlusion, 25. 8 (95% CI 21. 5 to 30. 
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9); and large-artery atherosclerosis, 15. 3 (95% CI 12 to 19. 3). 
When age-adjusted to the European population, the incidence rate 
for large-artery atherosclerosis was more than twice as high for men 
than for women (23. 6/100 000 versus 9. 2/100 000). Two years 
after onset, patients in the small-artery occlusion subgroup were 3 
times more likely to be alive than those with cardioembolism. 
Ischemic stroke subtype according to the TOAST criteria was a 
significant predictor for long-term survival, whereas subtype was 
not a significant predictor of long-term recurrence up to 2 years, 
both before and after adjustment for age and sex.  
 This prospective study was the first population-based study on 
incidence, recurrence, and long-term survival of ischemic stroke 
subtypes with the TOAST criteria used as a mechanism-based sub-
type classification scheme. The present population-based study 
used widely accepted standardized methods of case ascertainment 
and provides for the first time basic epidemiological data on causes 
of ischemic stroke in a European population.  
 Petty et al. [19] conducted another population-based study on 
incidence and risk factors for ischemic stroke subtypes. Authors 
identified all 454 residents of Rochester, Minn, with a first ischemic 
stroke between 1985 and 1989 from the Rochester Epidemiology 
Project medical records linkage system. We used Stroke Data Bank 
criteria to assign infarct subtypes after reviewing medical records 
and brain imaging. We adjusted average annual incidence rates by 
age and sex to the US 1990 population and compared the age-
adjusted frequency of stroke risk factors across ischemic stroke 
subtypes. This study reported age- and sex-adjusted incidence rates 
(per 100 000 population) were as follows: large-vessel cervical or 
intracranial atherosclerosis with >50% stenosis, 27; cardioembolic, 
40; lacuna, 25; uncertain cause, 52; other or uncommon cause, 4. 
Sex differences in incidence rates were detected only for atheroscle-
rosis with stenosis (47 [95% CI, 34 to 61] for men; 12 [95% CI, 7 to 
17] for women). There was no difference in prior transient ischemic 
attack and hypertension among subtypes, and diabetes was not 
more common among patients with lacunar infarction than other 
common subtypes. The age-adjusted incidence rate of stroke due to 
stenosis of the large cervicocephalic vessels is nearly 4 times higher 
for men than for women. There is no association between preceding 
transient ischemic attack and stroke mechanism. Diabetes and hy-
pertension are not more common among patients with lacunae. 
Age- and sex-adjusted incidence rates for ischemic stroke subtypes 
in this population can be compared with similarly determined rates 
from other populations.  
 Subtype-specific ischemic stroke incidence rates permit identi-
fication of racial and sex differences in stroke etiology. For exam-
ple, our study documents that men have a 4 times greater age-
adjusted incidence rate of ischemic stroke due to large-vessel athe-
rosclerosis than women. This biological difference could more than 
adequately explain why carotid endarterectomy rates in the United 
States are 30% to 60% higher for men than for women [20, 21]. 
Similarly, a comparison of our study and the study of the black 
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though black Americans have higher overall age- and sex-adjusted 
ischemic stroke incidence (246 per 100 000) compared with whites 
(147 per 100 000), the incidence of stroke due to large-vessel athe-
rosclerosis with stenosis is significantly greater among whites (27 
per 100 000) than blacks (17 per 100 000). This difference cannot 
be attributed to a disparity in procedure rates because the same 
proportion (54%) of patients in our study and in the study by Woo 
et al. received diagnostic tests to detect carotid stenosis. Clearly, 
biological differences in stroke mechanism as well as biological 
differences in the intracranial and extracranial distribution of athe-
rosclerosis between blacks and whites [23, 24] could account for a 
significant portion of the 2- to 3-fold higher carotid endarterectomy 
rates reported for whites compared with blacks in Massachusetts, 
California, and the Veterans Affairs Medical Centers. 8, 13-15 Sub-
type-specific stroke incidence rates thus permit an informed and 
objective assessment of various hypotheses that have been proposed 
to explain race and sex differences in cerebral angiography and 
carotid endarterectomy rates in the United States [25-28].  
 Much of the heterogeneity in stroke can be related to the preva-
lence of risk factors, but some populations have a higher stroke 
incidence than would be predicted from risk factor levels. Hyper-
tension, including borderline hypertension, is probably the most 
important stroke risk factor based on degree of risk and prevalence. 
However, cardiac morbidity, cigarette smoking, diabetes, physical 
inactivity, and high levels of alcohol consumption are also strongly 
related to stroke risk. High levels of blood cholesterol and homo-
cysteine may also increase stroke risk. Mortality after stroke is 
highest within the first 30 days but remains elevated to a degree that 
depends on the presenting stroke syndrome, stroke subtype, and 
other co-morbidities. Lacunar strokes have the best short- and long-
term prognoses. Strokes due to large-vessel atherosclerosis fre-
quently worsen; these and cardioembolic strokes have the poorest 
long-term prognosis. The risk for recurrence is also highest within 
30 days after a first stroke, depending on the type of infarct, history 
of hypertension, and blood glucose levels on admission. Predictors 
of late recurrence include cardiac disease, hypertension, and heavy 
alcohol use. Only about half of stroke survivors are independent 6 
months after a stroke, and quality of life is decreased. Understand-
ing factors that predispose to stroke and determine its outcome will 
help in the design of acute stroke trials and in prevention programs.  
 Incidence of ischaemic stroke subtypes, classified by cause, 
seems to vary between communities. Recently Lavados et al. [29] 
aimed to prospectively ascertain the incidence of first-ever ischae-
mic stroke in a predominantly Hispanic-Mestizo population in the 
northern desertic region of Chile. Between July, 2000, and June, 
2002, all patients with possible stroke or transient ischaemic attacks 
were identified from multiple overlapping sources and were rapidly 
assessed by two field neurologists. All identified patients were di-
agnosed by at least two stroke neurologists according to Trial of 
Org 10172 in Acute Stroke Treatment (TOAST) definitions and 
were followed up at 6 months. Annual incidence rates were age 
adjusted to WHO, European, and US populations by the direct 
method to allow comparisons. Authors identified a total of 239 
ischaemic strokes, of which 185 (77%) were first-ever cases. 151 
(82%) patients were hospitalised, of whom only 70 (38%) were 
assessed within 6 h of symptom onset. The mean age of patients 
was 66. 4 years (SD 14. 9) and 56% were men. The crude annual 
incidence rates (per 100 000) according to stroke subtype were: 
cardioembolic, 9. 3; large-artery disease, 2. 0; small-vessel disease, 
15. 8; other determined cause, 0. 2; and undetermined cause, 17. 4. 
Hypertension was the most common cardiovascular risk factor in all 
subtypes and atrial fibrillation was the most common cause of car-
dioembolic stroke. Case fatality at 30 days was highest in cardi-
oembolic strokes (28%) and lowest in small-vessel disease (0%). 
Dependency or death at 6 months was also highest in cardioembolic 
strokes (62%) and lowest in small-vessel disease (21%). Incidence 
and prognosis of small vessel and cardioembolic infarction was 
similar to that in other populations and incidence of large-artery 
atherothrombotic infarction was lower than in most previous re-
ports. Hypertension and atrial fibrillation were the most common 
risk factor and cause, respectively, of ischemic stroke in this popu-
lation. These findings should help the national stroke programme in 
the prevention of cardioembolic stroke, increase access to special-
ists and acute brain imaging and vascular studies, and improve 
stroke care.  
INFLAMMATORY MARKERS IN ACUTE ISCHEMIC 
STROKE 
 A nonspecific systemic inflammatory response occurs after 
both ischemic and hemorrhagic stroke, either as part of the process 
of brain damage or in response to complications such as deep ve-
nous thrombosis. Several studies have reported that higher levels of 
inflammatory markers such as C-reactive protein (CRP) and inter-
leukin-6 (IL-6) are associated with worse outcome after both 
ischemic [30] and hemorrhagic [31, 32] strokes. However, these 
studies often had methodological weaknesses, chiefly that they 
were too small, did not adequately adjust for confounders or assess 
the clinical utility of the measurements.  
 Chronic systemic inflammatory conditions, such as atheroscle-
rosis, diabetes and obesity are associated with increased risk of 
stroke, which suggests that systemic inflammation may contribute 
to the development of stroke in humans. The hypothesis that sys-
temic inflammation may induce brain pathology has been be tested 
in animals. Drake et al. [36] assessed inflammatory changes in the 
brain in rodent models of chronic, systemic inflammation. PET 
imaging revealed increased microglia activation in the brain of 
JCR-LA (corpulent) rats, which develop atherosclerosis and obe-
sity, compared to the control lean strain. Immunostaining against 
Iba1 confirmed reactive microgliosis in these animals. An athero-
genic diet in apolipoprotein E knock-out (ApoE(-/-)) mice induced 
microglial activation in the brain parenchyma within 8weeks and 
increased expression of vascular adhesion molecules. Focal lipid 
deposition and neuroinflammation in periventricular and cortical 
areas and profound recruitment of activated myeloid phagocytes, T 
cells and granulocytes into the choroid plexus were also observed. 
In a small, preliminary study, patients at risk of stroke (multiple risk 
factors for stroke, with chronically elevated C-reactive protein, but 
negative MRI for brain pathology) exhibited increased inflamma-
tion in the brain, as indicated by PET imaging. These findings show 
that brain inflammation occurs in animals, and tentatively in hu-
mans, harbouring risk factors for stroke associated with elevated 
systemic inflammation. Thus a "primed" inflammatory environment 
in the brain may exist in individuals at risk of stroke and this can be 
adequately recapitulated in appropriate co-morbid animal models.  
 Stroke triggers an intense inflammatory response that could be 
a consequence of Toll-like receptors (TLRs) activation. However, 
the clinical significance and the therapeutic possibilities of TLR in 
stroke is not completely clear. In this study, we analyze the associa-
tion between the expression of TLR2 and TLR4, inflammatory 
molecules and endogenous ligands, and clinical outcome of 
ischemic stroke patients, and we test the potential of TLR2/TLR4 
and their endogenous ligands as therapeutic targets. For this pur-
pose Brea et al. [35] included 110 patients with ischemic stroke 
finding that TLR2 and TLR4 are independently associated to poor 
outcome and correlated with higher serum levels of interleukin 
(IL)1, IL6, tumor necrosis factor , and VCAM1, and that TLR4 
was independently associated to lesion volume. In addition, authors 
have developed an in vitro model to test the potential therapeutic 
value of blocking TLR2/TLR4 or their endogenous ligands. Cul-
tured cells (monocytes and human umbilical vein endothelial cells) 
were treated with serum from ischemic stroke patients, showing a 
strong inflammatory response that was blocked when TLR2/4 or 
cellular fibronectin (cFN) or HSP60 were blocked. In conclusion, 
TLR2 and TLR4 are associated to outcome in stroke patients and 
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TLR2/4 or their endogenous ligands, cFN/HSP60 could be new 
therapeutic targets for ischemic stroke.  
 Previous studies have shown that the concentration of periph-
eral inflammatory markers, particularly C-reactive protein (CRP), 
strongly correlates with stroke severity and independently predicts 
mortality and recurrent vascular events in patients with acute 
ischemic stroke. Youn et al. [35] conducted a study to clarify the 
relationship between inflammatory markers and stroke severity by 
means of volumetric measurement of infarct size. 96 patients who 
had laboratory investigations and magnetic resonance imaging 
scans were included retrospectively in this study. Diffusion-
weighted imaging (DWI) lesions were outlined using a semiauto-
matic threshold technique. Diffusion-weighted imaging lesion vol-
umes were measured with MIPAV software (Medical Image Proc-
essing, Analysis and Visualization, version 4. 1. 1; National Insti-
tutes of Health, Bethesda, MD). The relationship between highly 
selective CRP (hs-CRP) levels and DWI infarct volume quartiles 
was examined. The mean age of patients was 66. 9 years, and 50 
patients (51. 2%) were male. There was a significant correlation 
between hs-CRP and DWI volumes (Spearman  = 0. 239, P = . 
010). The median hs-CRP values for successive volumes of DWI 
lesion quartiles (lowest to highest quartile) were as follows: 1. 17, 
1. 14, 1. 63, and 3. 76 (P = . 029). Higher hs-CRP levels were asso-
ciated with larger infarct volumes in patients with acute ischemic 
stroke. These results suggest that elevated hs-CRP levels, reflecting 
a large volume of infarct, may serve as a helpful serologic marker 
in the evaluation of severity of acute ischemic stroke.  
 Animal research has characterized postischemic inflammation 
as a multi-facetted response involving activation of resident glia 
cells and recruitment of blood-derived leucocytes as well as cas-
cades of humoral responses [35-36]. In the classical transient mid-
dle cerebral artery occlusion (tMCAO) model, hematogeneous cells 
including polymorphonuclear neutrophils (PMN) and macrophages 
rapidly infiltrate the ischemic region [37-40].  
 Neuroinflammation evolves as a multi-facetted response to 
focal cerebral ischemia. It involves activation of resident glia cell 
populations, recruitment of blood-derived leucocytes as well as 
humoral responses. Among these processes, phagocyte accumula-
tion has been suggested to be a surrogate marker of neuroinflamma-
tion. Walberer et al. [41] in a rat model of permanent focal ische-
mia by embolisation of TiO2-spheres assessed key features of post-
ischemic neuroinflammation by the means of histology, immunocy-
tochemistry of glial activation and influx of hematogeneous cells, 
and quantitative PCR of TNF-, IL-1, IL-18, and iNOS mRNA. In 
the boundary zone of the infarct, a transition of ramified microglia 
into ameboid phagocytic microglia was accompanied by an up-
regulation of MHC class II on the cells after 3 days. By day 7, a 
hypercellular infiltrate consisting of activated microglia and phago-
cytic cells formed a thick rim around the ischemic infarct core. 
Interestingly, in the ischemic core microglia could only be observed 
at day 7. TNF- was induced rapidly within hours, IL-1 and iNOS 
peaked within days, and IL-18 later at around 1 week after ische-
mia. The macrosphere model closely resembles the characteristical 
dynamics of postischemic inflammation previously observed in 
human stroke. Authors therefore suggest that the macrosphere 
model is highly appropriate for studying the pathophysiology of 
stroke in a translational approach from rodent to human. Few data 
exist on the relationship between differential subpopulations of 
peripheral leukocytes and early cerebral infarct size in ischemic 
stroke. Using diffusion-weighted MR imaging (DWI), we assessed 
the relationship of early total and differential peripheral leukocyte 
counts and volume of ischemic tissue in acute stroke. A recent 
study [42] included patents that had laboratory investigations and 
neuroimaging collected within 24 hours of stroke onset. Total pe-
ripheral leukocyte counts and differential counts were analyzed 
individually and by quartiles. DWI lesions were outlined using a 
semiautomated threshold technique. The relationship between leu-
kocyte quartiles and DWI infarct volumes was examined using 
multivariate quartile regression. 173 patients met study inclusion 
criteria. . Total leukocyte counts and DWI volumes showed a strong 
correlation (Spearman rho=0. 371, P<000. 1). Median DWI vol-
umes (mL) for successive neutrophil quartiles were: 1. 3, 1. 3, 3. 2, 
and 20. 4 (P for trend <0. 001). Median DWI volumes (mL) for 
successive lymphocyte quartiles were: 3. 2, 8. 1, 1. 3, and 1. 5 (P=0. 
004). After multivariate analysis, larger DWI volume remained 
strongly associated with higher total leukocyte and neutrophil 
counts (both probability values <0. 001), but not with lymphocyte 
count (P=0. 4971). Compared with the lowest quartiles, DWI vol-
umes were 8. 7 mL and 12. 9 mL larger in the highest quartiles of 
leukocyte and neutrophil counts, respectively. Higher peripheral 
leukocyte and neutrophil counts, but not lymphocyte counts, are 
associated with larger infarct volumes in acute ischemic stroke. 
Attenuating neutrophilic response early after ischemic stroke may 
be a viable therapeutic strategy and warrants further study Granulo-
cytes are the first hematogenous cells that appear in the brain in 
response to focal ischemia.  
 After permanent occlusion of the MCA they accumulated in 
cerebral vessels within hours [43] before they invaded the infarct 
and its boundary zone. This process peaked at 24 hr after infarction, 
thereafter the number of granulocytes rapidly declined. At day 7 
granulocytes were only occasionally seen. Granulocyte infiltration 
was preceded by an increased expression of cytokine-induced neu-
trophil chemoattractant (CINC) [44]. There is evidencethat in-
travascular granulocyte accumulations reduce blood flow in the 
reperfusion phase and thereby contribute to extension of infarctions 
in transient cerebral ischemia, while the pathophysiological conse-
quences of the parenchymal granulocyte invasion are unclear at 
present.  
 In addition to granulocytes, a significant number of T cells 
identified by immunocytochemistry invaded the infarct region [45]. 
After both permanent MCAO and photochemically induced ische-
mia, CD5+ T cells started to infiltrate the infarct region from day 1 
onwards. At day 3 their number had increased and reached a peak 
around day 7 followed by a substantial decrease within the next 7 
days. T cells were preferentially located in the boundary zone of the 
infarctions often in close vicinity to blood vessels. The presence of 
T cells was surprising. T cell recruitment into the central nervous 
system (CNS) is usually observed in autoimmune and inflammatory 
diseases such as experimental autoimmune encephalomyelitis 
(EAE) [46].  
 Although cells of the central nervous system (CNS) constitu-
tively express very low levels of MHC antigens, and express very 
low levels of MHC antigens, and are thus considered as ‘immu-
nologically silent’, these cells, once stimulated, can express various 
cytokines and adhesion molecules. Three major cytokines, namely, 
tumor necrosis factor (TNF , interleukin (IL)-1 , and IL-6 are pro-
duced by cultured brain cells after various stimuli. TNF- is pro-
duced by astrocytes when the cells are stimulated by lipopolysac-
charide (LPS), interferon (IFN)-7, and IL-l  [47]. Cultured astro-
cytes also produce high levels of IL-6, IL-8, granulocyte colony 
stimulating factor (G-CSF), M (macrophage)-CSF, and GM-CSF 
mRNAs and proteins when stimulated by IL-l  or TNF [48]. Frei 
et al. [49] showed that GM-CSF and M-CSF were produced by 
astrocytes after stimulation with TNFa, IL-l, and LPS, suggesting 
that activated astrocytes may be responsible for the accumulation 
and activation of monocytes/microglia in the area of tissue injury.  
 Adipose tissue secretes numerous proinflammatory cytokines 
and is involved in the regulation of glucose metabolism. A study by 
Wang et al. [50] aimed to determine the effects of acute stroke on 
adipose inflammatory cytokine expression. In addition, because 
sympathetic activity is activated after acute stroke and catechola-
mines can regulate the expression of several adipocytokines, this 
study also evaluated whether alterations in adipose proinflamma-
tory cytokines following acute stroke, if any, were medicated by 
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sympathetic system. Acute ischemic brain injury was induced by 
ligating the right middle cerebral artery and bilateral common ca-
rotid arteries in male adult Sprague-Dawley rats. Adipose tumor 
necrosis factor- (TNF-) and monocyte chemoattractant protein-1 
(MCP-1) mRNA and protein levels were determined by RT-PCR 
and enzyme-linked immunoassay, respectively. The stroke rats 
developed glucose intolerance on days 1 and 2 after cerebral 
ischemic injury. The fasting blood insulin levels and insulin resis-
tance index measured by homeostasis model assessment were 
higher in the stroke rats compared with the sham group. Epididymal 
adipose TNF- and MCP-1 mRNA and protein levels were elevated 
one- to twofold, in association with increased macrophage infiltra-
tion into the adipose tissue. When the rats were treated with a non-
selective -adrenergic receptor blocker, propranolol, before induc-
tion of cerebral ischemic injury, the acute stroke-induced increase 
in TNF- and MCP-1 was blocked, and fasting blood insulin con-
centration and homeostasis model assessment-insulin resistance 
were decreased. These results suggest a potential role of adipose 
pro-inflammatory cytokines induced by the sympathetic nervous 
system in the pathogenesis of glucose metabolic disorder in rats 
with acute ischemic stroke. 
 During the course of brain ischemia, inflammatory mechanisms 
both intrinsic to brain as well as blood are among the important 
mediators of focal cerebral injury [51]. With the onset of focal brain 
ischemia, microglia become activated within the penumbra and 
thereby facilitate further local neuronal injury via pathways that 
include poly(ADP-ribose) polymerase-1 activation and activation of 
multiple matrix metalloproteinases (MMPs). The activation of 
MMPs disrupts the blood-brain barrier, alters microvascular endo-
thelial function and impairs the functional integrity of the neurovas-
cular unit. These events promote the entry of peripheral leukocytes 
into brain and expose “protected” cerebral elements to peripheral 
immune surveillance systems.  
 Cerebral ischaemic injury is associated with the induction of a 
series of inflammatory events, including the infiltration of circulat-
ing immune cells (neutrophils and monocytes) and activation of 
resident cells, including microglia, astrocytes and endothelial cells 
[51]. These cells can express, release and respond to pro-
inflammatory mediators such as cytokines [5]. As inflammation is a 
ubiquitous response to tissue injury, this is to be expected; however, 
it is clear from experimental data.  
 Animal models of focal ischaemia induced by middle cerebral 
artery occlusion (MCAO) provide most evidence for cellular in-
flammatory responses in stroke. Permanent MCAO results in a 
modest neutrophil infiltration at 24 h after ischaemia, predomi-
nantly around arterial vessels at the margins of infarction, whereas 
MCAO with subsequent reperfusion is associated with substantial 
infiltration by neutrophils throughout the entire infarct [52]. Neu-
trophil accumulation in small vessels including capillaries in the 
peri-infarct region may contribute to the ‘no reflow’ phenomenon - 
a failure of tissue to reperfuse despite recanalization of the main 
vessel occluded [53].  
 Inflammatory cells such as neutrophils and macrophages infil-
trate into the ischemic brain in various animal models of ischemic 
stroke [53, 54, 55]. According to an animal study using the rat [54] 
ubjected to permanent middle cerebral artery occlusion (MCAO), 
polymorphonuclear leukocytes first appeared in the capillary lumen 
at 30 min, peaked at 12 h, whereas they first appeared in the paren-
chyma at 12 h, peaked at 24 h, and diminished in number thereafter. 
In addition, inherent cells such as astrocytes, microglia, or endothe-
lia have been found to be activated by cerebral injuries including 
ischemic stroke. These cells then become immunologically reactive 
and interact with each other by producing substances including 
cytokines and adhesion molecules. These molecules appear to be 
responsible for the accumulation of inflammatory cells in the in-
jured brain, and the resulting immunologic-inflammatory cascade 
produces an environment that may affect the survival of neurons 
subjected to ischemic injury constitutively express very low levels 
of MHC antigens, and are thus considered as ‘immunologically 
silent’, these cells, once stimulated, can express various cytokines 
and adhesion molecules.  
 Three major cytokines, namely, tumor necrosis factor (TNF, 
interleukin (IL)-1, and IL-6 are produced by cultured brain cells 
after various stimuli.  
 The differences between models lead to problems in character-
izing the therapeutic response to inhibitors of neutrophil migration 
and marked clinical heterogeneity in timing of reperfusion may 
have contributed to the failure of such agents to show benefit in 
clinical trials.  
 On this basis in acute stroke, there are therefore several areas in 
which inflammation may be relevant: as an indication of underlying 
vascular disease predisposing to stroke; as a precipitating process 
acting as a trigger for an acute event; once a stroke has occurred, as 
an acute response to tissue injury, possibly with a role in exacerbat-
ing the injury or its consequences; as a prognostic marker in the 
acute phase of stroke; or as a prognostic marker for recurrent car-
diovascular events - both stroke and extracerebral events. Any or all 
of these might give rise to therapeutic targets.  
 In this review, we provide basic science evidence concerning 
role of inflammation in neuronal damage after acute ischemic 
stroke and we will discuss some potential inflammatory therapeutic 
targets in acute stroke treatment. 
 Elevated levels of C-reactive protein (CRP), a proinflammatory 
marker, are associated with reduced systemic endothelium-
dependent NO-mediated dilation in patients with coronary artery 
disease; however, the direct effect of CRP on coronary microvascu-
lar reactivity remains unknown. Herein, Qamirani et al. [56] exam-
ined whether CRP can modulate endothelium-dependent NO-
mediated dilation of coronary arterioles and whether proinflamma-
tory signaling pathways such as stress-activated protein kinases 
(p38 and c-Jun N-terminal kinase [JNK]) and oxidative stress are 
involved in the CRP-mediated effect. Porcine coronary arterioles 
were isolated and pressurized without flow for in vitro study. In-
traluminal treatment with a clinically relevant concentration of CRP 
(7 microg/mL; 1 hour) significantly attenuated the NO release and 
vasodilation to serotonin. Further incubation with the NO precursor 
l-arginine (3 mmol/L) partially restored serotonin-induced vasodila-
tion. In the presence of superoxide scavenger 4-hydroxy-2, 2, 6, 6-
tetramethylpiperidine-1-oxyl (TEMPOL), NAD(P)H oxidase inhibi-
tor apocynin, or p38 kinase (an upstream activator of NAD(P)H 
oxidase) inhibitor SB203850, but not xanthine oxidase inhibitor 
allopurinol or JNK inhibitor SP600125, the detrimental effect of 
CRP on serotonin-induced dilation was prevented. Dihydroethidium 
staining showed that CRP produced SB203850- and TEMPOL-
sensitive superoxide production in the arteriolar endothelium. CRP 
treatment of coronary arterioles significantly increased NAD(P)H 
oxidase activity. Authors concluded that CRP inhibits endothelium-
dependent NO-mediated dilation in coronary arterioles by produc-
ing superoxide from NAD(P)H oxidase via p38 kinase activation. 
By impairing endothelium-dependent NO-mediated vasoreactivity, 
CRP could facilitate the initiation of numerous cardiovascular dis-
eases.  
 Furthermore CRP seems to have a direct pathogenetic role in 
brain ischemia . Increased mortality after stroke is associated with 
brain edema formation and high plasma levels of the acute phase 
reactant C-reactive protein (CRP). A recent study [57] was de-
signed to examine whether CRP directly affects blood-brain barrier 
stability and to analyze the underlying signaling pathways. Authors 
used a cell coculture model of the blood-brain barrier and the 
guinea pig isolated whole brain preparation and they showed that 
CRP at clinically relevant concentrations (10 to 20 microg/mL) 
causes a disruption of the blood-brain barrier in both approaches. 
The results of this study further demonstrate CRP-induced activa-
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tion of surface Fc receptors CD16/32 followed by p38-mitogen-
activated protein kinase-dependent reactive oxygen species forma-
tion by the NAD(P)H-oxidase. The resulting oxidative stress in-
creased myosin light chain kinase activity leading to an activation 
of the contractile machinery. Blocking myosin light chain phos-
phorylation prevented the CRP-induced blood-brain barrier break-
down and the disruption of tight junctions. These data identify a 
previously unrecognized mechanism linking CRP and brain edema 
formation and present a signaling pathway that offers new sites of 
therapeutic intervention 
 Several studies [58-60] show that C-reactive protein (CRP), an 
inflammatory marker, is associated with stroke outcomes and future 
vascular events. It is not clear whether this is due a direct dose-
response effect or rather an epiphenomenon. Idicula et al. [61] stud-
ied the effect of CRP measured within 24 hours after stroke onset 
on functional outcome, mortality and future vascular events. 
Authors prospectively studied 498 patients with ischemic stroke 
who were admitted within 24 hours after the onset of symptoms. 
CRP and NIH stroke scale (NIHSS) were measured at the time of 
admission. Short-term functional outcome was measured by modi-
fied Rankin scale (mRS) and Barthel ADL index (BI) 7 days after 
admission. Patients were followed for up to 2. 5 years for long-term 
mortality and future vascular events data. The median CRP at ad-
mission was 3 mg/L. High CRP was associated with high NIHSS (p 
= 0. 01) and high long-term mortality (p < 0. 0001). After adjusting 
for confounding variables, high CRP remained to be associated 
with high NIHSS (p = 0. 02) and high long-term mortality (p = 0. 
002). High CRP was associated with poor short-term functional 
outcomes (mRS > 3; BI < 95) (p = 0. 01; p = 0. 03). However, the 
association was not significant after adjusting for confounding vari-
ables including stroke severity (p = 0. 98; p = 0. 88). High CRP was 
not associated with future vascular events (p = 0. 98). Authors con-
cluded that admission CRP is associated with stroke severity and 
long-term mortality when measured at least 24 hours after onset. 
There is a crude association between high CRP and short-term 
functional outcome which is likely secondary to stroke severity. 
CRP is an independent predictor of long-term mortality after 
ischemic stroke.  
 Recent investigations [62-66] demonstrated that mRNAs of 
above cytokines were induced in the ischemic rat brain. TNF- is a 
pleiotropic cytokine that mediates key roles in many physiological 
and pathological cellular processes including acute and chronic 
inflammation, programmed cell death or apoptosis, anti-tumor re-
sponses, and infection [67].  
 The source of these circulating cytokines in patients with 
ischemic stroke remains unknown. However, Tarkowski et al. [68] 
serially measured serum and cerebrospinal fluid IL-l /3 and IL-6 in 
patients with ischemic stroke and found that the levels of these 
cytokines were much higher in the cerebrospinal fluid than in the 
serum. These results are highly suggestive of intrathecal production 
of the cytokines. The level of early production of IL-6 in cerebro-
spinal fluid was found to be significantly correlated with the size of 
brain lesion. In addition, Mathiesen et al. [69] found markedly 
(more than 300 fold) increased level of IL-6 in cerebrospinal fluid 
following subarachnoid hemorrhage, which was not paralleled by 
the amount of the cytokine in the serum. The elevation of cytokine 
was more marked at day 6 than day 3 or 9, and could be associated 
with the development of delayed ischemic deficits. Increased levels 
of IL-l and IL-6 in ventricular fluid was also detected in patents 
with severe head injuries [70] .  
 A growing body of evidence from studies using both preclinical 
animal models and human samples collected from ischemic stroke 
patients suggests TNF is also involved in the development of 
ischemic brain lesions. TNF is rapidly expressed in ischemic brain 
after the onset of the disease [71]. The upregulation of TNF also 
leads to the damage of the blood brain barrier (BBB) [72], as well  
 
as neuronal cell death during the stroke [73]. On the one hand, TNF 
was shown to be responsible for the neuronal death in an oxygen-
glucose deprivation (OGD) model in vitro and in an ischemic brain 
damage model in vivo [74]. TNF- is also involved in apoptotic 
death of neurons exhibiting peripherin aggregates [73]. BALB/C 
mice pretreated with F- intracisternally 48 h prior to MCAO 
also showed significant reduction in infarct size [75], presumably 
through the induction of the ischemic preconditioning (IPC) which 
can be protective against subsequent brain injury.  
 Interleukin-1 (IL-1) family consists of IL-1, IL-1 converting 
enzyme (ICE)/caspase-1, IL-1, IL-1 receptors I (IL-1RI) and II 
(IL-1RII), and IL-1 receptor antagonist (IL-1ra) IL-1 is cleaved 
from the precursor protein, pro-IL- 1, by ICE. IL-1RI is a signal-
ing receptor, whereas IL-1RII is a truncated receptor that serves as 
a decoy to inhibit IL-1 activity . IL-1ra is an endogenous protein 
that inhibits. IL-1 activity by competitive binding to the IL-1RI 
[76]. Increased expression of IL-1 and IL-1RI in hypoxic brain 
cells [44] and peri-infarct tissues [77, 78] has been linked to 
ischemic brain injury. Clinical studies have shown that intrathecal 
[79] and systemic [80, 81] increases in IL-1, interleukin-8 (IL-8) 
and interleukin-17 (IL-17) correlate with neurological impairment 
in stroke patients. 
 On this basis the presence of an inflammatory response in the 
pathophysiology of acute brain ischemia is relatively well estab-
lished. Cytokines such as interleukin-6 (IL-6), tumor necrosis fac-
tor- (TNF-) appear to be crucial mediators of such responses, 
however much remains unknown about their complex interactions 
in the setting of clinical stroke [82, 83].  
 Increased production of pro-inflammatory cytokines has been 
observed in experimental models of brain ischemia as well as in 
patients with acute stroke [84, 85] and may be associated with large 
cerebral infarct volume and poor stroke outcome [86, 87].  
 Inflammatory cytokine families and their receptors expressed in 
brain tissue may be exploited as drug targets to control brain in-
flammation resulting from the ischemic insult. Several strategies 
have been tested to block inflammatory effects of cytokines and 
chemokines, including neutralizing antibodies, soluble cyto-
kine/chemokine receptors, inhibitors of cytokine/chemokine syn-
thesis, and anti-inflammatory cytokines.  
 The balance between pro-inflammatory and anti-inflammatory 
cytokine molecules is altered in the early phase of acute ischemic 
stroke. Some investigators have reported the role of IL-10 as the 
main downregulator of deleterious effect of proinflammatory cyto-
kines [88, 89].  
 Kes et al. [90] to explore the difference in concentration of IL-
6, TNF- and IL-10 between acute ischemic stroke patients and 
control individuals analyzed the association of plasma cytokine 
concentration with stroke severity at admission assessed by NIHSS 
as prognostic score and stroke outcome in 90 days assessed by 
Barthel index (BI) and modified Rankin scale (mRS). These authors 
showed that Il-6 was increased in patients relative to controls and 
this increase was associated with severe stroke and worse outcome 
(assessed by BI and mRS, respectively), whereas IL-10 was de-
creased and associated with better outcome.  
 On this basis An immunoinflammatory cascade. involving en-
dothelial and coagulation functions represents the pathogenetic 
background of neuronal damage in ischemic stroke. Indeed, there is 
evidence that brain injury, secondary to arterial occlusion, is char-
acterized by acute local inflammation 
INFLAMMATION IN ACUTE STROKE SUBTYPES 
 Clinical studies have reported increased levels of proinflamma-
tory cytokines and adhesion molecules in the peripheral blood and 
cerebrospinal fluid (CSF) of patients with ischemic stroke.  
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 High IL-6 concentrations in CSF and plasma have been associ-
ated with larger infarct size, neurological deterioration, and poor 
outcome independently of the stroke subtype.  
 However, although accumulating evidence suggests that in-
flammatory-mediated damage plays a role in brain ischemia, for 
long time it remains unclear whether inflammation also intervenes 
in a same intensity in each diagnostic subtype of ischemic stroke.  
 Castellanos et al. [91] sought to investigate the role of proin-
flammatory molecules in the early worsening and outcome of acute 
lacunar stroke. Authors performed a secondary analysis of 113 
consecutive patients with lacunar infarction included within the first 
24 hours of the onset of symptoms in a previous study aimed at 
investigating clinical and biochemical factors of early neurological 
deterioration (END). END was defined as a fall of > or =1 points in 
the motor items of Canadian Stroke Scale between inclusion and 48 
hours. Poor outcome at 3 months was considered death or Barthel 
Index <85. Interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-
alpha), and intercellular adhesion molecule-1 (ICAM-1) were de-
termined by enzyme-linked immunoabsorbent assay in blood sam-
ples obtained on admission. END was recorded in 27 patients (23. 
9%); poor outcome was noted in 26 (23%). Median (quartiles) con-
centrations in plasma of TNF-alpha [16. 5 pg/mL (13. 7 and 21. 2 
pg/mL) versus 7. 5 pg/mL (6. 2 and 9. 0 pg/mL)], IL-6 [28. 8 
pg/mL (22. 5 and 35. 7 pg/mL) versus 11. 5 pg/mL (8. 5 and 16. 2 
pg/mL)], and ICAM-1 [285 pg/mL (219 and 315 pg/mL) versus 158 
pg/mL (137 and 187 pg/mL)] were significantly higher in patients 
who had END than in those with nonprogressing strokes (P< 0. 
001). Significant differences were also observed between patients 
with poor and good outcome at 3 months. Logistic regression 
analysis after adjustment for potential confounders showed that 
TNF-alpha >14 pg/mL and ICAM-1 >208 pg/mL were independ-
ently associated with both END (OR, 511; 95% CI, 17 to 4937; 
P<0. 001; and OR, 315; 95% CI, 17 to 5748; P< 0. 001, respec-
tively) and poor outcome at 3 months (OR, 3. 0; 95% CI, 1. 0 to 8. 
5; P=0. 042; and OR, 4. 2; 95% CI, 1. 3 to 13. 6; P<0. 015, respec-
tively).  
 This study demonstrates in a large series of patients with lacu-
nar infarctions an independent association of high levels of inflam-
matory molecules in blood with END and poor outcome. The effect 
of these compounds on END was stronger because the outcome 
depends particularly on baseline stroke severity. The mechanisms 
involved in END of lacunar infarctions have not been clearly estab-
lished, and it seems unlikely that those factors currently accepted as 
contributing to worsening in other stroke subtypes offer a full ex-
planation in the case of lacunar stroke.  
 TNF- promotes the expression of adhesion molecules such as 
ICAM-1 on the endothelium, facilitating leukocyte adherence and 
migration from capillaries into the brain, microvessel occlusion, 
and subsequently a progressive reduction in blood flow [92, 93]. 
The accumulation of polymorphonuclear neutrophil leukocytes in 
the ischemic area as a result of the inflammatory process has been 
proved in a few clinical observations with brain scintigraphy or 
brain SPECT with labeled leukocytes. 37, 38 High levels of TNF- 
have been detected as soon as 15 hours in brain samples of stroke 
victims, peaking during days 2 and 3, 39 and plasma determinations 
after acute stroke have demonstrated an early activation of ICAM-
1, which peaks within 24 hours of cerebral ischemia [94, 95]. These 
findings are in accordance with our results because we found in-
creased TNF- and ICAM-1 levels within 24 hours (mean, 11 
hours) of the onset of lacunar stroke. High levels of adhesion mole-
cules may reflect a prior condition of chronic endothelial activation 
secondary to risk factors for atherosclerosis such as hypertension, 
which was significantly more frequent in our patients who had 
END. In this study, however, high ICAM-1 levels remained inde-
pendently associated with subsequent END after controlling for the 
history of hypertension in the logistic analysis.  
 An interesting finding in this study is that inflammatory mole-
cules contributed to END after adjustment for glutamate and GABA 
concentrations in blood and that the ORs for TNF- and ICAM-1 
were even higher than that for glutamate concentrations. These 
results suggest that inflammation may have an additional and 
stronger role than excitotoxicity in END of lacunar infarctions. On 
the other hand, inflammatory and excitatory mechanisms might 
cooperate in the progression of lacunar stroke because we have 
found a significant correlation between glutamate or GABA con-
centration and inflammatory markers in blood. Furthermore, as 
occurred with amino acid concentrations, [96] authors have ob-
served higher levels of inflammatory molecules in patients with 
lacunar infarctions located in basal ganglia and brainstem than in 
those with white matter infarctions, so excitotoxicity and inflamma-
tion might represent sequential and interacting processes in the 
progression of lacunar stroke, particularly in brain areas with a high 
density of glutamatergic neurons [97]. This hypothesis is supported 
by experimental data suggesting that cytokines influence glutamate 
receptor mediated excitotoxicity.  
 A study by Sotgiu et al. [98] was designed to evaluate the se-
rum concentrations of a panel of biomarkers known to be variably 
associated with ischemic stroke (IL-1b, TNF-a, IL-6, IL-8, MCP-1, 
VCAM-1, ICAM-1, MMP-2/9 and the brain-derived neurotrophic 
factor, BDNF) in a consecutive series of patients with acute brain 
ischemia without concomitant infections, and to correlate their level 
with the extent of brain lesion as documented by computed tomo-
graphy (CT) and neurological outcome both at study entry and at 3-
month period.  
 Infarct size was calculated on computed tomography (CT) scans 
by means of the Cavalieri's method. Neurological impairment was 
scored by using the Glasgow Coma Scale, Glasgow Outcome Scale 
and National Institutes of Health (NIH) scales at stroke onset and 3-
month follow-up. Some markers showed a direct significant corre-
lation with both initial and final NIH scale and with infarct size, 
particularly tumor necrosis factor alpha (TNF-alpha) (P=0. 002), 
intercellular adhesion molecule-1 (P<0. 01) and matrix metallopro-
teinase-2/9 (P=0. 001). In contrast to previous reports, interleukin-6 
(IL-6) serum level showed a significant inverse correlation with 
both final neurological impairment and infarct size (P<0. 001). This 
novel finding allows the authors suggesting that IL-6, in the context 
of a complex pro-inflammatory network occurring during stroke, is 
associated with neuroprotection rather than neurotoxicity in patients 
with ischemic brain injury.  
 It has become increasingly evident that the inflammatory re-
sponse plays an important role in the pathogenesis of neuronal 
damage following stroke. Pro-inflammatory cytokines, including 
tumor necrosis factor (TNF)-, interleukin (IL)-1 and IL-6 are 
secreted in the ischemic region by activated immune cells, which 
drive the inflammatory process and accelerate additional inflamma-
tory processes by inducing inflammatory molecules, such as inter-
cellular adhesion molecules (ICAM), vascular cell adhesion mole-
cules-1 (VCAM-1) and selectins [99]. These inflammatory modula-
tors recruit more circulating leukocytes that infiltrate into the 
ischemic region and lead to further loss of neuronal cells and brain 
tissue, resulting in an increase of cerebral infarct size [99, 100, 101] 
 Recently our group [102] conducted a study with the aim to 
evaluate possible differences in the immunoinflammatory activation 
of acute phase and in thrombotic/fibrinolitic pathway (TPA and 
PAI-1 plasma levels) in stroke patients in relation to time of symp-
toms onset, diabetic state and diagnostic subtype of stroke. We 
enrolled 60 consecutive patients with a diagnosis of acute ischemic 
stroke (32 with type 2 diabetes and 28 non-diabetics), admitted to 
the Internal Medicine Department at the University of Palermo 
between November 2002 and January 2005, and 123 consecutive 
hospitalized control patients without a diagnosis of acute ischemic 
stroke. Stroke was defined by focal neurological signs or symptoms 
thought to be of vascular origin that persisted for >24 hours, con-
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firmed by brain CT and /or MRI in baseline conditions and brain 
CT with contrast medium after 48-72 hours. Patients were defined 
as type 2 diabetics if they had known diabetes treated with diet, oral 
hypoglycemic drugs or insulin before stroke. We excluded patients 
with stress hyperglycaemia and new onset diabetes because we 
intended to analyze only chronic hyperglycaemia effects on immu-
noinflammatory activation. Patients with inflammatory or infectious 
diseases, acute myocardial infarction (AMI), venous thromboem-
bolism (DVT or EP), cancer, hematological diseases and severe 
renal or liver failure, as well as those who were under treatment 
with anti-inflammatory drugs, were excluded. The type of acute 
ischemic stroke was classified according to the TOAST classifica-
tion (6): 1) Large artery atherosclerosis (LAAS); 2) cardioembolic 
infarct (CEI); 3) LACunar infarct (LAC); 4) stroke of other deter-
mined etiology (ODE); 5) stroke of undetermined etiology (UDE). 
All the ischemic stroke patients had medical history recording po-
tential stroke risk factors and underwent; blood and coagulation 
tests; 12-lead ECG; 24 hour electrocardiography monitoring; 
transthoracic echocardiography; carotid ultrasound; brain CT or 
MRI at admission (repeated between the third and the seventh days 
of stroke onset).  
 Blood samples from each subject enrolled were drawn within 
72 hours from and 7-10 days after symptoms onset and they were 
centrifuged (10. 000 g), and the resulting supernatant was immedi-
ately frozen at -80°C until analysis was completed. We evaluated 
plasma levels of IL-1, TNF-, IL-6 and IL-10, E-selectin, P-
selectin, sICAM-1 and sVCAM-1 as markers of immunoinflamma-
tory activation, VWF plasma levels as a marker of endothelial dys-
function, TPA antigen and PAI-1 plasma levels as a marker of a 
prothrombotic state. Neurological deficit score at Scandinavian 
Stroke Scale (SSS) on admission and disability degree at discharge 
by Rankin disability scale were obtained for stroke patients. SSS 
assesses neurological deficit through an evaluation of consciousness 
level, eye movement, strength in the arms, hand and legs, orienta-
tion, language, facial weakness and gait, giving rise to a score rang-
ing from 58 (absence of deficit) to 0 (death). According to the 
modified Rankin disability score, functional ability after stroke was 
graded by a score ranging from 1 (no significant disability) to 6 
(death).  
 Stroke patients exhibited significantly higher plasma levels of 
PAI-1. Of the stroke patients, 31 were classified as lacunar and 29 
as non-lacunar. Concerning inflammatory variables, the stroke pa-
tients versus controls exhibited, at 24-72h after stroke onset, higher 
levels of IL-1 , TNF-, E-Selectin, VCAM-1, ICAM-1, VWF and 
white body cells (WBC ). Among our stroke patients, diabetic sub-
jects vs non-diabetics were significantly younger [68 yrs (63-72) vs 
78 yrs (68-88); p=0. 004]. Diabetics also showed no significant 
difference regarding the plasma levels of immunoinflammatory 
variables, but exhibited significantly higher plasma levels of PAI-1 
[163 pg/ml (127. 5-192. 5) vs 125 pg/ml (104. 75-159); p=0. 03]. 
To evaluate immunoinflammatory activation in relation to diagnos-
tic subtype, we examined the relationship between the analyzed 
variables and TOAST subtype, respectively lacunar and non-
lacunar The patients with lacunar stroke in comparison with non-
lacunar ones were significantly younger [66. 5 yrs (60-76. 5) vs 75 
yrs (66-86); p=0. 007), had significantly higher glucose blood lev-
els (217. 5 mg/dl (101-244) vs 107 mg/dl (96-226); p=0. 025] and a 
significantly higher SSS score [45 (47-50. 7) vs 36 (9-39); p=0. 
0001). Moreover, with regard to immuno-inflammatory variables, 
the patients with lacunar strokes in comparison with subjects with 
non-lacunar stroke exhibited, 24-72h after stroke onset, lower 
plasma levels of IL-1 and TNF- . At 7-10 days after stroke onset 
TNF- [83. 5 pg/ml (65. 25-200) vs 258 pg/ml (140-1000); p=0. 
001] and IL-1 [5 pg/ml (3-8. 75) vs 8 pg/ml (5-11); p=0. 0001] 
plasma levels remained lower in patients with lacunar stroke, but 
subjects with non-lacunar stroke also exhibited higher plasma levels 
of P-selectine [4. 5 ng/ml (1. 8-6. 5) vs 1. 8 ng/ml (2. 17-5. 95); 
p=0. 04] and ICAM-1[19. 1 ng/ml (17-23) vs 15. 6 ng/ml (14. 25 -
22. 75); p=0. 01]. Moreover, to assess possible differences in rela-
tion to diabetes, patients with lacunar and non-lacunar stroke were 
further evaluated in relation to diabetic or non-diabetic state. Dia-
betic patients with lacunar stroke in comparison with non-diabetic 
patients with lacunar stroke and in comparison with diabetics and 
non-diabetics with non-lacunar stroke, were significantly younger 
[64 yrs (60-71) vs 78 yrs (64-78. 5) vs 69 yrs (64. 2-81. 7) vs 81 yrs 
(68-89); p=0. 001), had significantly higher systolic blood pressure 
levels [165 mmHg (135-175) vs 155 mmHg (153. 7-171. 2) vs 150 
(141. 2-155. 7; p=0. 0001], significantly lower diastolic blood pres-
sure (DBP) levels (82. 5 mmHg (80-96. 2) vs 95 mmHg (92. 5-95) 
vs 92. 5 mmHg (75-100 ) vs 90 mmHg (80-100); p=0. 0001] and a 
significantly higher SSS score [50 (45. 5-50. 2) vs 47. 5 (47-51) vs 
37(31-40. 7) vs 34 (2-39); p=0. 0001].  
 Concerning inflammatory variables, the diabetic patients with 
lacunar stroke in comparison with non-diabetic patients with lacu-
nar stroke and in comparison with diabetics and non-diabetics with 
non-lacunar stroke exhibited, 24-72h after stroke onset, signifi-
cantly lower levels of IL-1, TNF- and ICAM-1. In diabetic pa-
tients with lacunar stroke, 7-10 days after stroke onset, plasma lev-
els of TNF- [64. 5 pg/ml (40. 5-99. 2) vs 145 pg/ml (92-415) vs 
467 pg/ml (171. 2-550) vs 314. 5 pg/ml (88. 7-447); p=0. 001], IL-
1 [3. 5 pg/ml (1-5) vs 6 pg/ml (5-6. 25) vs 6 pg/ml (4. 2-11. 5) vs 8 
pg/ml (6-10); p=0. 013] and ICAM-1 [14. 9 ng/ml (11. 8-19. 2) vs 
16. 2 ng/ml (14. 3-17. 7) vs 19. 2 (15-21) vs 18. 4 (15. 2-22); p=0. 
006] remained significantly lower in comparison with non-diabetic 
patients with lacunar stroke and with diabetics and non-diabetics 
with non-lacunar stroke .  
 Our study, consistent with published data, [103, 104] we ob-
served higher plasma levels of IL-1, TNF-, IL-6, E and P se-
lectin, ICAM-1 and VCAM-1 and VWF in stroke patients in com-
parison to control subjects without acute ischemic stroke. It has 
been assumed that IL-1  is the primary form of IL-1 involved in 
ischemic brain damage [104-107] TNF- plays a pivotal role in 
inflammatory processes that increase leukocyte-endothelial cell 
adhesion molecule expression, increase leukocyte adherence to 
blood vessels and their subsequent infiltration into the brain, and 
activates the endothelium for pro-coagulation activity [105]. Inter-
leukin-6 (IL-6) is an inflammatory cytokine which can damage the 
endothelium and lead to the initiation of atherosclerosis, and it is 
also related to ischemic neural damage and clinical worsening 
[107].  
 On the other hand, we also report no significant difference in 
IL-1, TNF-, IL-6 E and P selectin, ICAM-1 and VCAM-1 and 
VWF plasma levels between diabetic and non-diabetic stroke pa-
tients, but diabetics, in comparison to non-diabetic ones, exhibited 
higher plasma levels of PAI-1. This result is particularly interesting 
and could be related to three factors:  
1. The role of PAI-1 as acute phase molecule [108].  
2. The reported induction of plasminogen activator inhibitor 
type-1 by hyperglycemia, hyperinsulinaemia and precursor of 
insulin [109] that in diabetic subjects, and particularly in dia-
betic stroke patients, are particularly high.  
3. The prothrombotic state of the diabetic subjects [110].  
 Therefore, this possibly accounts for the immunoinflammatory 
activation of the acute phase of stroke, but probably reflects the 
metabolic pattern of diabetes, and it could partially explain the re-
ported higher recurrence of ischemic stroke in diabetic subjects .  
Our study could highlight possible peculiarities of acute cerebral 
ischemia in diabetics in comparison with non-diabetics and our 
results appear particularly interesting regarding the differences of 
immunoinflammatory activation in relation to TOAST subtype. In 
fact, patients with lacunar strokes in comparison with subjects with 
non-lacunar strokes, exhibited, 24-72h after stroke onset, signifi-
cantly lower levels of TNF- and IL1-. TOAST classification 
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underlined that ischemic stroke is not a unique pathological condi-
tion but a group of neurological syndromes with different etiologic, 
clinical and prognostic features, so it is possible that each diagnos-
tic subtype could be characterized by a different pathogenetic sub-
strate with various grades of immunoinflammatory activation. Pos-
sibly this lower intensity of cytokines activation of the acute phase 
could be related to the lower extent of lacunar strokes, with a possi-
ble relationship between lower TNF- and IL-1  plasma levels of 
the acute phase and the minor acute neurological deficit of lacunar 
subtype, previously reported by our group [111, 112] and also re-
ported in this study. Furthermore, 7-10 days after stroke onset, this 
trend of inflammatory activation is confirmed with additional evi-
dence of significantly higher levels of P-Selectin in patients with 
non-lacunar strokes in comparison to subjects with lacunar ones, 
owing to a possibly less rapid slope in levels of this inflammation 
mediator in comparison to lacunar patients. P-Selectin, as a result of 
platelet activation and endothelial damage, plays an important role 
in the pathogenesis of ischemic infarct [112]. Indeed P-Selectin 
expression leads to adhesion of leukocytes and subsequent release 
of cytokines and oxygen radicals, activation of coagulation and 
stimulation of endothelial cells and platelets, in an ongoing cycle of 
neural tissue damage. Our findings regarding a higher increase of P-
selectin plasma levels 7-10 days after stroke onset, in patients with 
non-lacunar stroke vs subjects with lacunar ones, could underline 
the contribution of atherosclerotic vascular disease to the increase 
of soluble adhesion molecules, and probably suggests the important 
role of leukocytes and platelets in the late-acute phases of brain 
infarction, particularly in atherothrombotic strokes.  
 In our study, lacunar stroke of diabetic patients appears to be 
peculiar in comparison with non-diabetic lacunar stroke. The for-
mer are characterized by significantly lower levels of IL1 and 
TNF-, both at 24-72h and 7-10 days after stroke. This interesting 
finding could explain our previous data [110, 111] concerning a 
more favorable outcome in diabetic patients owing to the higher 
prevalence of lacunar strokes and it could provide a possible expla-
nation for this issue, based on the minor grade of immunoinflamma-
tory activation of both early and late acute phase of ischemic stroke 
in these patients, possibly related to the minor extent of ischemic 
brain damage. It is likely that a minor grade of chronic inflamma-
tory response in cerebral small vessels could be involved in diabetic 
brain microangiopathy owing to the minor diameter of the patho-
genesis of the diabetic lacunae [113]. Moreover, we observed a 
lower grade of ICAM 1 activation in diabetic patients with lacunar 
stroke. Intracellular adhesion molecule-1 (ICAM-1) is a member of 
the immunoglobulin superfamily and the principal ligand for the 
leukocyte function-associated antigen-1 (LFA-1), a member of the 
integrin superfamily [114]. One function of ICAM-1/LFA-1 adhe-
sion system is to assist leukocyte movement into tissue and LFA-1 
is constitutively expressed by brain microglial cells [114]. Our find-
ing is possibly related to a lower extension of lacunar infarcts with 
a lower grade of recruitment of leukocytes into infarct area and 
consecutively with a minor release of bioactive substances, e. g. 
reactive oxygen metabolites, granular enzymes or cytokines, that 
induce damage to neural cells.  
 In conclusion, it is very clear that ischemic stroke is a multifac-
torial and dynamic process. We have confirmed the immunoin-
flammatory activation of the acute phase in patients with acute 
ischemic stroke and we measured the temporal event from stroke-
onset-dependent relationship between inflammation of the acute 
phase, diabetic state and diagnostic subtype with particularly lower 
median plasma levels of TNF-, IL1, P-selectin and ICAM-1 in 
lacunar diabetic patients. Therefore, the degree of inflammatory 
response to ischemic stroke may be variable. A possible explana-
tion for this variability, in addition to the infarct size, stroke sub-
type, time from symptoms onset and metabolic background as we 
report in our study, could be the genetic control of immunoinflam-
matory response related to polymorphism of the candidate genes, as 
recently shown by Pola et al. [115] who reported how proinflamma-
tory genetic genotypes (IL-6 GG, ICAM-1 EE, E-Selectin AA) are 
significantly more common in subjects with stroke history. Only 
prospective, well-designed studies will provide the currently lack-
ing information and will gradually improve our knowledge in the 
field of genetic polymorphisms in acute ischemic stroke practice 
 At extracranial arterial territories, inflammation plays a crucial 
role mediating all the stages of the atherosclerosis process [116] 
Similarly, thrombosis and defective fibrinolysis may also contribute 
to the progression of atherosclerotic lesions [117]. Interestingly, 
both mechanisms might have a relevant role in the pathogenesis of 
intracranial large artery atherosclerosis and ischemic stroke.  
 On this basis, it would be interesting to evaluate inflammatory 
and plasma levels of thrombotic/fibrinolytic markers in relation to 
each diagnostic subtype of ischemic stroke.  
 One study examined the inflammatory pathway in the lacunar 
subtype [118] whereas no study, to our knowledge, evaluated the 
inflammatory pathway in other subtypes of ischemic stroke. 
Fewstudies have examined the relationship between blood levels of 
inflammatory biomarkers and stroke outcome [119].  
 On this basis we conducted another study with the aim to 
evaluate, in patients with acute ischemic stroke, plasma levels of 
immuno-inflammatory markers, and endogenous activators and 
inhibitors of fibrinolysis plasma levels in relation to the diagnostic 
subtype of stroke, and to evaluate the relationship between these 
variables with clinical outcome and infarct site.  
 In our study [] we enrolled patients with a diagnosis of acute 
ischemic stroke admitted to the Internal Medicine Department at the 
University of Palermo and to the Neurology Division of Azienda 
Ospedaliera Civico of Palermo between November 2006 and Octo-
ber 2008. The control subjects were patients admitted, in the same 
period, to our Internal Medicine Department for any cause different 
from acute cardiovascular and cerebrovascular events or exclusion 
criteria. Every subject with ischemic stroke was matched for age 
(±3 years), sex, and cardiovascular risk factor prevalence with one 
control subject.  
 In our previous work [120] we compared only lacunar stroke 
with non-lacunar strokes (LAAS, CEI and ODE), but in this previ-
ous work the small number of subjects enrolled (n=60) did not al-
low us to analyse immuno-inflammatory profile of the acute phase 
of ischemic stroke of each diagnostic subtype, due to the fact that 
when divided into subgroups the numbers become even smaller, 
enhancing the possibility of chance skewing that could become 
significant. Nevertheless, in our present study we present data of 
new enrolled 107 (according sample size calculation) patients with 
ischemic stroke, so it was feasible to divide our enrolled patients 
into subgroups in relation to TOAST diagnostic subtype and evalu-
ate cytokine, selectins and adhesion molecules with regard to each 
diagnostic subtype.  
 Stroke was defined by focal neurological signs or symptoms 
thought to be of vascular origin that persisted for N24 h, confirmed 
by brain CT and/or MRI in baseline conditions. In order to match 
patients with acute ischemic stroke and controls for cardiovascular 
risk and previous cardiovascular morbidity, controls were included 
if they had vascular risk factors or a history of myocardial infarc-
tion, cerebrovascular disease or peripheral vascular disease, but 
they were excluded if they had either current or recent (up to 6 
months) cerebrovascular disease or one of the other exclusion crite-
ria (see Exclusion criteria section). Cardiovascular risk factors were 
evaluated for both subjects and controls on the basis of the follow-
ing criteria: type 2 diabetes was determined using a clinically based 
algorithm that considered age at onset, presenting weight and symp-
toms, family history, onset of insulin treatment, and history of ke-
toacidosis. Atrial fibrillation was diagnosed when present on the 
admission ECG. Hypertension was present when a patient had re-
ceived antihypertensive treatment before admission or when hyper-
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tension was diagnosed during the hospital stay by repeated detec-
tion of blood pressure 160/95 mm/Hg. Hypercholesterolemia was 
defined as total serum cholesterol 200 mg/dl or on the basis of a 
clinical history of hypercholesterolemia or statin treatment.  
 Patients with inflammatory or infectious diseases, cancer, hae-
matological diseases and severe renal or liver failure, as well as 
those who were under treatment with anti-inflammatory drugs were 
excluded. We also excluded patients with fever, recent venous 
thromboembolism and rheumatologic disease.  
 The type of acute ischemic stroke was classified according to 
the TOAST classification [15]: 1) Large Artery Athero-Sclerosis 
(LAAS); 2) CardioEmbolic Infarct (CEI); 3) LACunar infarct 
(LAC); 4) stroke of Other Determined Etiology (ODE); 5) stroke of 
UnDetermined Etiology (UDE).  
 All the ischemic stroke patients underwent: medical history 
with recording of potential stroke risk factors, blood and coagula-
tion tests, 12-lead ECG, 24 h electrocardiography monitoring, trans-
thoracic echocardiography, carotid ultrasound, brain CT or MRI at 
admission (repeated between the third and the seventh days of 
stroke onset). Blood samples were obtained in the non-fasting state. 
After 10 min of rest in the supine position, vital signs were recorded 
and blood samples were collected from the antecubital vein. EDTA-
anticoagulated peripheral blood was drawn from each patient within 
12 h from symptom onset. Serum and plasma were immediately 
separated by centrifugation and stored in aliquots at 80 °C until 
analysis.  
 We evaluated plasma levels of IL-1, TNF-, IL-6 and IL-10, 
E-selectin, P-selectin, sICAM-1 and sVCAM-1 as markers of im-
munoinflammatory activation, VWF plasma levels as a marker of 
endothelial dysfunction, TPA-antigen and PAI-1 plasma levels as 
thrombotic/fibrinolytic markers.  
 We enrolled 107 subjects with acute ischemic stroke and 102 
matched controls (without ischemic stroke). Among stroke patients, 
according to TOAST Classification, 41 were classified as LAAS, 
32 as lacunar, 31 as CEI and 3 as ODE. Stroke patients in compari-
son with controls showed significantly higher median plasma levels 
of IL1-, IL-6, TNF-, E-Selectin P-Selectin VCAM-1 and ICAM-
1. Interestingly, patients with cardioembolic subtype showed a sig-
nificantly lower median Scandinavian Stroke Scale Score [29 (23-
39)] compared to other subtypes, whereas stroke patients classified 
as lacunar showed a significantly higher median SSS score [46. 5 
(47-50. 7)].  
 Patients with ischemic stroke classified as cardioembolic (CEI) 
showed, compared to other subtypes, significantly higher median 
plasma levels of TNF- [37. 2 (21. 2-48)); pb0. 0001], IL-6 [12 (6. 
5-18); p=0. 0029 ], IL-1 [13. 5 (7-17); pb0. 0001], whereas plasma 
levels of Von Willebrand factor in patients with cardioembolic 
subtype were higher in comparison with other subtypes but were 
only near a statistical significance [12 (6-13) (p=0. 0053). No sig-
nificant difference in terms of plasma levels of throm-
botic/fibrinolytic markers was observed between each stroke sub-
type Furthermore, stroke patients classified as lacunar showed, 
compared to other subtypes, significantly lower median plasma 
levels of TNF- [18. 4 (11-23) pg/ml; pb0. 0001]; IL-6 [5 (2-8) 
pg/ml; p=0. 0029) ], IL-1 [4 (2-10) pb0. 0001 )], whereas plasma 
levels of Von Willebrand factor in [5 (2-9) ng/ml] patients with 
lacunar subtype were lower in comparison with other subtypes, but 
were only nearly at statistical significance.  
 Interestingly, among patients with lacunar stroke, no significant 
difference in median plasma levels of TNF-, IL-6 and IL-1 was 
observed between subjects with and without a lacunar detectable 
lesion on neuroimaging (respectively 16. 8 pg/ml, 9. 5 pg/ml and 7 
pg/ml vs 17. 2, pg/ml, 10 pg/ml, 6. 8 pg/ml; p=0. 87). Multiple 
linear regression performed to investigate associations between 
some relevant variables and SSS score as a dependent variable 
showed a significant association between SSS score at admission 
and diagnostic subtype: lacunar (b=3. 71; p=0. 029) ] or [cardioem-
bolic (b=-8. 011; p=0. 0007)] and some inflammatory variable 
[TNF- (b=-0. 010; pb0. 0001) or IL-6 (b=-0. 068; pb0. 0001)1].  
 Our findings showed that patients with acute ischemic stroke 
compared to controls without stroke have significantly higher me-
dian plasma levels of some immune-inflammatory markers and 
significative difference in comparison with controls with regard of 
plasma levels of some thrombotic/fibrinolytic markers such as PAI-
1 and TPA.  
 We also showed that subjects with cardioembolic TOAST sub-
type showed significantly higher plasma levels of TNF-, IL-6 and 
IL-1, whereas lacunar subtype showed significantly lower plasma 
levels of these cytokines, whereas no significative difference was 
observed among each TOAST subtype of stroke with regard of 
thrombotic/fibrinolytic marker plasma levels. Our study further 
supports the hypothesis that inflammation may have an important 
role in the pathogenesis of ischemic strokes, but it also suggests the 
hypothesis of a peculiar immuno-inflammatory pattern as a patho-
genic background of every subtype of ischemic stroke.  
 Cerebral ischemia initiates a complex cascade of events at ge-
nomic, molecular, and cellular levels, and inflammation is impor-
tant in this cascade, both in the Central Nervous System (CNS) and 
in the periphery. The entire spectrum of inflammatory processes is 
likely to act in concert but cytokines are important mediators of 
stroke induced immunological/inflammatory reactions, which con-
tribute to brain infarct progression as well as to the disease severity 
and outcome [119]. Indeed cytokines may have various functions 
during cerebral ischemia, on the one hand, they can attract leuko-
cytes and stimulate the synthesis of adhesion molecules in leuko-
cytes, endothelial cells, and other cells, thus promoting the inflam-
matory response of damaged cerebral tissue. On the other, they can 
facilitate thrombogenesis by increasing the levels of plasminogen-
activating inhibitor-1 tissue factor (PAI-1), and platelet activating 
factor and by inhibiting tissue plasminogen activator and protein 
[121]. Clinical studies [122, 123] have reported increased levels of 
proinflammatory cytokines and adhesion molecules in the periph-
eral blood and cerebrospinal fluid (CSF) of patients with ischemic 
stroke. Among the cytokines involved in the pathogenesis of 
ischemic stroke, TNF- is activated in experimental ischemia at 
both the mRNA and protein levels.  
 Furthermore, increased levels of cytokines such as interleukin 
IL-1, tumor necrosis factor- (TNF-), and IL-6, as well as adhe-
sion molecules such as intercellular adhesion molecule-1 (ICAM-
1), have been observed after experimental brain ischemia.  
 A question that arises is, does a relationship between differen-
tial immuno-inflammatory activation of the acute phase in each 
TOAST subtype and stroke prognosis? In our study patients with 
cardioembolic strokes, in comparison with other subtypes, showed 
a higher degree of acute neurological deficit at admission evaluated 
by SSS scale and a higher degree of immuno-inflammatory activa-
tion of the acute phase. On the other hand in patients with lacunar 
stroke, compared to other subtypes, we observed a lower grade of 
acute neurological deficit at admission evaluated by SSS scale and 
a lower degree of immuno-inflammatory activation of the acute 
phase.  
 Moreover, regression analysis of stroke subtype (lacunar or 
cardioembolic) and plasma levels of IL-6 and TNF- were the vari-
ables more strictly associated with clinical outcome in terms of SSS 
score, with cardioembolic subtype and higher plasma levels of these 
cytokines associated with a poor clinical outcome and lacunar sub-
type, and lower plasma levels of cytokines associated with a better 
outcome.  
 In our study, logistic regression analysis showed a significant 
relationship between some inflammatory markers (TNF-, IL-6) 
and demographic variables (age), diagnostic subtype (lacunar or 
cardioembolic) and SSS score. Age is a widely described outcome 
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predictor, but particularly interesting is the apparent link between 
diagnostic subtype, immuno-inflammatory activation of the acute 
phase and prognosis. In our study cardioembolic strokes showed the 
highest grade of immuno-inflammatory activation of the acute 
phase and the lowest SSS score as expression of a highest neuro-
logical deficit of the acute phase. In general, cardioembolic strokes 
have a worse prognosis and produce larger and more disabling 
strokes than other ischemic stroke subtypes [124, 125]. Infarct size 
could represent a possible factor influencing plasma levels of im-
muno-inflammatory markers. Although this issue is not always 
investigated and confirmed [126, 127] , it is conceivable that other 
factors could represent an additional factor that influence immuno-
inflammatory activation after acute ischemic stroke. Our patients 
with lacunar stroke with no lesion detectable on brain CT or MRI 
do not show any significant difference with regard to cytokine 
plasma levels of the acute phase compared to patients with lacunar 
lesions (CT or MRI detectable). So beyond a possible direct rela-
tionship between infarct size and cytokine levels, infarct site 
could also have an additional weight on immuno-inflammatory 
activation of the acute phase. Interestingly, in our patients most 
of the lacunar strokes had a subcortical location, whereas most of 
the cardioembolic strokes had a cortical location. In particular, in 
our patients with lacunar stroke with a sub-cortical location, most 
were detected in the basal ganglia and thalamus and only a minority 
in the corona radiata. Sub-cortical infarcts have been classified into 
two pathogenically different types: striatocapsular infarcts and ter-
minal supply area infarcts [128] fected structures of large striato-
capsular infarcts include the caudate head, anterior limb of the in-
ternal capsule, and the putamen corresponding to the territories of 
the lenticulostriate arteries [129, 130]. On the other hand, terminal 
supply area infarcts are not located in the basal ganglia themselves 
but in the more rostral periventricular and supraventricular white 
matter of the corona radiate and the centrum semiovale [130]. 
White matter infarcts in these two regions, resulting from relatively 
reduced perfusion in two or three neighboring arterial supply areas, 
have been called together “terminal supply area infarcts. ” How-
ever, they occur simultaneously in some patients and separately in 
others. Zulch's work [131] has shown that periventricular white 
matter of the corona radiata is the watershed zone between the deep 
and superficial territories of the MCA. population of patients with 
atrial fibrillation (AF) is growing markedly with the increasing 
number of the elderly [132] . In general, the prognosis of cardio-
embolic stroke tends to be poor as a result of obstruction of the 
major brain arteries by large fibrin-rich thrombi to produce large 
brain infarcts [133]. Cerebral ischaemia initiates a complex cascade 
of events at genomic, molecular, and cellular levels, and inflamma-
tion is important in this cascade, both in the central nervous system 
(CNS) and in the periphery [134, 135] . Furthermore, recent re-
search points to the role of chemokines, normally key factors in 
inflammation, in thrombogenesis [136], probably also explaining 
hyper-responsiveness of platelets in ischaemic stroke [137]. Re-
cently our group reported that lacunar strokes compared to non-
lacunar ones exhibited significantly lower plasma levels of tumour 
necrosis factor (TNF)- and interleukin (IL)1-, P-selectin and 
intercellular adhesion molecule 1 (ICAM-1) 24-72 hours (h) and 7-
10 days after stroke onset [138]. One previous study examined in-
flammatory pathways in lacunar study [139], whereas no study, to 
our knowledge, evaluated inflammatory pathways in acute cardi-
oembolic strokes. Furthermore, few studies have examined the 
relationship between blood levels of inflammatory biomarkers and 
stroke outcome [118, 119], but data on a relation between inflam-
mation parameters and diagnostic subtype remain scarce.  
 We conducted another study [138] to evaluate cytokines, select-
ins and adhesion molecule plasma levels in patients with acute 
ischaemic stroke in relation to diagnostic subtype and to evaluate 
the relationship between clinical, laboratory and immuno-
inflammatory variables and acute neurological deficit of cardioem-
bolic strokes in comparison with other stroke subtypes.  
 We chose to evaluate these biomarkers because acute ischaemic 
stroke has been associated with serum elevations of a series of im-
muno-inflammatory variables such as TNF-, IL-6, IL1-, selectins 
adhesion molecules and of markers of impaired haemostasis and 
thrombosis. Thus, it appears that inflammation, mediated by both 
molecular components, including cytokines, selectins and adhesion 
molecules and cellular components, such as leukocytes and micro-
glia may be important in the mechanisms of cerebral injury and 
repair.  
 We enrolled all consecutive patients with a diagnosis of acute 
ischaemic stroke admitted to the Internal Medicine and Cardio-
Angiology Department at the University of Palermo (Italy) between 
November 2002 and January 2006. Controls were patients admitted, 
in the same period, to our department for any cause other than acute 
cardiovascular and cerebro-vascular events or exclusion criteria 
(see exclusion criteria section).  
 Stroke was defined by focal neurological signs or symptoms 
thought to be of vascular origin that persisted for >24 h confirmed 
by brain computed tomography (CT) and /or magnetic resonance 
imaging (MRI) scan in baseline conditions and brain CT with con-
trast medium after 48-72 h (19).  
 In order to also match patients with acute ischaemic stroke and 
controls for cardiovascular risk and previous cardiovascular mor-
bidity, controls were included if they had vascular risk factors or a 
history of myocardial infarction or cerebrovascular disease or pe-
ripheral vascular disease, but they were excluded if they had either 
current or recent (up to six months) cerebro-vascular disease or one 
of the exclusion criteria.  
 We enrolled 156 subjects with acute ischaemic stroke and 123 
matched controls (without ischaemic stroke). Among stroke pa-
tients, according to TOAST Classification, 50 were classified as 
LAAS, 46 as lacunar, 20 as CEI and 4 as ODE.  
 Stroke patients compared to controls showed significantly 
higher median plasma levels of IL1-, IL-6, TNF-, E-selectin P-
selectin V-CAM-1 and ICAM-1. The mean ischaemic lesion vol-
ume on brain CT was 1077. 7 mm3. The brain lesion mean volume 
was larger in patients with cardio-embolic stroke infarction (mean 
12273 mm3) than in those with atherosclerotic lesions (mean 11894 
mm3) and lacunar infarct (mean 9894 mm3).  
 Interestingly, patients with cardio-embolic subtype showed a 
significantly lower median SSS score [29 (11-34)] compared to 
other subtypes, whereas stroke patients classified as lacunar showed 
a significantly higher median SSS score [49. 5 (47-50. 7)].  
 Patients with ischaemic stroke classified as cardio-embolic 
(CEI), compared to other subtypes, showed significantly higher 
median plasma levels of TNF- [38. 5 (22. 2-46) pg/ml; p< 0. 
0001], IL-6 [11 (5. 5-19) pg/ml; p=0. 0029], IL1- [11. 5 (8-13) 
pg/ml; p<0. 0001] , whereas plasma levels of VWF in patients with 
cardio-embolic subtype were higher compared to other subtypes but 
were only near statistical significance [10 (5-12) ng/ml ( p= 0. 
0053)]. Furthermore, stroke patients classified as lacunar showed, 
compared to other subtypes, significantly lower median plasma 
levels of TNF- [19. 4 (9-23) pg/ml; p< 0. 0001]; IL-6 [(4 (2-9) 
pg/ml; p=0. 0029) ], IL1- [6 (10-3) pg/ml p< 0. 0001 )] whereas 
plasma levels of VWF [6 (3-8) ng/ml (0. 0057)] in patients with 
lacunar subtype were lower in comparison with other subtypes, but 
were only near statistical significance. Patients with LAAS subtype 
of acute ischaemic stroke compared with subjects with cardio-
embolic subtype had a lower mean brain infarct volume (11894 
mm3 vs. 12273 mm3) and significantly lower median plasma val-
ues of TNF- [27. 5 (13. 4-40. 5) pg/ml vs. 38. 5 (22. 2-46) pg/ml] , 
IL-6 [8 (4-12) pg/ ml vs. 11 (5. 5-19)pg/ml], IL1- (9 (5-10, 5) 
pg/ml vs. 11. 5 (8-13) pg/ml] . No significative difference was ob-
served between each TOAST subtype with regard of ICAM-1, 
VCAM-1, E-selectin, P-selectin, VWF, PAI-1 and TPA plasma 
levels.  
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 Nevertheless comparing only the seven patients among LAAS 
and CEI strokes, that were comparable on the basis of matched 
mean brain infarct volume (11350 mm3 vs. 11455 mm3), patients 
with cardio-embolic stroke showed similar median plasma levels of 
TNF- [26. 2 (11. 4-37. 5) pg/ml vs. 26. 7 (11. 9-38. 1) pg/ml, IL-6 
[7 (3-11) pg/ml vs. 7. 5 (5. 5-13) pg/ml], IL1- [10 (5-11. 5) pg/ml 
vs. 11. 5 (8-13) pg/ml] and similar mean SSS score (34 vs. 33).  
 Infarct sites at brain CT in relation to TOAST diagnostic sub-
type. Interestingly, among patients with lacunar stroke no signifi-
cant difference in median plasma levels of TNF-, IL-6 and IL1- 
was observed between subjects with and without a lacunar detect-
able lesion on neuroimaging (19. 8pg/ml, 9 pg/ml and 6 pg/ml vs. 
18. 9, pg/ml, 10 pg/ml, 5. 5 pg/ml, respectively; p = 0. 87).  
Multiple linear regression performed to investigate associations 
between some relevant variables and SSS score as a dependent 
variable showed a significant association between SSS score at 
admission and diagnostic subtype: lacunar (b=3. 206; p=0. 0338) ] 
or [cardio-embolic (b= -7. 819; p = 0. 0006)], infarct volume of 
cardio-embolic strokes and some inflammatory variable [TNF- (b 
=-0. 013; p < 0. 0001) or IL-6 (b= -0. 074; p < 0. 000)1].  
 Our findings show that among patients with acute ischaemic 
stroke, patients with cardio-embolic subtype showed significantly 
higher plasma levels of TNF-, IL-6 and IL1-, whereas lacunar 
subtype showed significantly lower plasma levels of these cytoki-
nes. Our study further supports the hypothesis that inflammation 
may have an important role in the pathogenesis of ischaemic 
strokes, but our findings also suggest a peculiar immuno-
inflammatory pattern in each subtype of acute ischaemic stroke.  
 The first cells responding to brain ischaemia are glial cells, 
particularly microglia, with transcription of early pro-inflammatory 
cytokines such as IL1- and TNF- able to activate additional in-
flammatory pathways leading to induction of nitric oxide, adhesion 
molecules and IL-6 [118, 119].  
 Patients with cardio-embolic strokes, in comparison with other 
subtypes, showed a higher degree of acute neurological deficit at 
admission evaluated by SSS scale and a higher degree of immuno-
inflammatory activation of the acute phase. On the other hand in 
patients with lacunar stroke, compared to other subtypes, we ob-
served a lower degree of acute neurological deficit at admission 
evaluated by SSS scale and a lower degree of immuno-
inflammatory activation of the acute phase. Nevertheless, patients 
with LAAS stroke subtype showed higher median plasma levels of 
some immuno-inflammatory markers (TNF-, IL-6 and IL1-) 
compared to lacunar subtype, but lower median plasma levels of 
these biomarkers compared to the CEI subtype .  
 Our finding concerning higher plasma levels of immuno-
inflammatory markers in patients with cardio-embolic stroke under-
lines the role of inflammation in the pathogenesis of cerebral car-
dio-embolism. Evidence is growing that inflammation may be asso-
ciated with AF [139] and it may underlie pathogenesis of the 
arrhythmia [140]. Inflammation leads to the adhesion, recruitment 
and trans-endothelial migration of leucocytes into the intimae, 
which is mediated by adhesion molecules on the endothelial cell 
membrane; leading to the initial capture and rolling of leucocytes 
along the endothelium [141].  
 Patients with cardio-embolic stroke showed a significantly 
lower median SSS score compared to patients with other subtypes 
of stroke, whereas patients with lacunar stroke showed a signifi-
cantly higher SSS score compared to other clinical subtypes of 
stroke. Moreover, on regression analysis stroke subtype (lacunar or 
cardio-embolic), infarct volume of cardio-embolic stroke and 
plasma levels of IL-6 and TNF- were the variables most strictly 
associated with acute neurological deficit evaluated by SSS score, 
with cardio-embolic subtype and higher plasma levels of these cy-
tokines associated with a poor clinical presentation (lower SSS 
score) and lacunar subtype and lower plasma levels of cytokines 
associated with a better clinical presentation (higher SSS score).  
 Infarct size could represent a possible factor influencing im-
muno-inflammatory marker plasma levels, although this issue is not 
always confirmed [141-142], but it is conceivable that other factors 
could represent an additional factor that influence immuno-
inflammatory activation after acute ischaemic stroke. Indeed 
ischaemic brain injury secondary to arterial occlusion is character-
ized by acute local inflammation, which involves accumulation of 
poly-morphonuclear neutrophils (PMN). Factors that influence the 
recruitment of PMN on infarct site could modify local cytokine 
production. Identification of factors involved in the selective re-
cruitment and accumulation of inflammatory cells into ischaemic 
brain tissue is likely to expand our understanding of the mecha-
nisms that result in transient or permanent neurological deficits, but 
the mechanisms behind the entry of leukocytes to sites of ischaemia 
are not well understood.  
 Nevertheless in 25% to 40% of patients with ischaemic stroke, 
neurological symptoms progress during the initial hours [143-144]. 
Although several clinical, radiological, and biochemical factors 
have been associated with early neurological deterioration, most of 
them have a low predictor value [145-146]. Regarding our patients 
with lacunar stroke, about 20% of our patients did not have visible 
infarction on CT or MRI, which is similar to the results of previous 
studies [147, 148].  
 Our patients with lacunar stroke with no lesion detectable on 
brain CT or MRI do not show any significant difference with regard 
to cytokine plasma levels of the acute phase compared to patients 
with lacunar lesion (CT- or MRI-detectable). So beyond a possible 
direct relationship between infarct size and cytokine levels, infarct 
site could also have an additional role in immunoinflammatory 
activation of the acute phase. Interestingly, in our patients most of 
the lacunar strokes had a sub-cortical location, whereas most of the 
cardio-embolic strokes had a cortical location . In particular in our 
patients with lacunar stroke and a sub-cortical location, most were 
located in basal ganglia and thalamus and only a minority in corona 
radiata. Subcortical infarcts have been classified into two patho-
genically different types: striatocapsular infarcts and terminal sup-
ply area infarcts [147, 148].  
 Arterial stiffness is increasingly recognized as an important 
determinant of cardiovascular risk [151-152] and it may be directly 
involved in the process of atherosclerosis [152]. Factors underlying 
increased arterial stiffness are not well understood, but both func-
tional and structural alterations in the vessel wall are thought to be 
important. Clinical studies evaluated arterial stiffness in patients 
with cardiovascular risk factors such as hypertension [153-156], 
diabetes [157], and end-stage renal disease [158], whereas only one 
study [159] analyzed pulse wave velocity (PWV) in stroke patients 
although, in this study, they did not have controls for comparison of 
their findings.  
 No study has evaluated both arterial stiffness indexes (pulse 
wave velocity and augmentation index) in patients with an acute 
cardiovascular or cerebrovascular event.  
 On this basis we conducted a study [160] to evaluate arterial 
stiffness indexes in subjects with acute ischemic stroke and to 
evaluate the relationship between these indexes and other clinical 
and laboratory variables.  
 The hypothesis of our study was that in acute phase of ischemic 
stroke values of markers of arterial stiffness could be increased 
compared to control subjects without acute ischemic stroke, be-
cause immuno-inflammatory activation, endothelial dysfunction 
and other potentially toxic events characteristic of the acute phase 
of stroke. Further assumption was that, in relation to the different 
pathogenesis of each TOAST subtype, markers of arterial stiffness 
could have different values in different TOAST subtype.  
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 We enrolled all consecutive patients with a diagnosis of acute 
ischemic stroke admitted to the Internal Medicine Department at the 
University of Palermo between November 2006 and January 2009, 
and hospitalized control patients without a diagnosis of acute 
ischemic stroke. Control subjects were patients admitted, in the 
same period, to our Internal Medicine Department for any cause 
other than acute cardiovascular and cerebrovascular events.  
 Inclusion criteria were: a diagnosis of acute ischemic stroke 
defined by focal neurological signs or symptoms thought to be of 
vascular origin that persisted for >24 h, confirmed by brain CT 
and/or MRI in baseline conditions and brain CT with contrast me-
dium after 48-72 h. Exclusion criteria were: age <18 years and >80 
years, acute myocardial infarction (AMI), haemorrhagic stroke.  
 In order to match patients with acute ischemic stroke and con-
trols also for cardiovascular risk and previous cardiovascular mor-
bidity, controls were included if they had vascular risk factors or a 
history of myocardial infarction or cerebrovascular disease or pe-
ripheral vascular disease, but they were excluded if they had either 
current or recent (up to six months) cerebrovascular disease or one 
of the exclusion criteria (see above).  
 The type of acute ischemic stroke was classified according to 
the TOAST classification [15]: (1) Large-Artery AtheroSclerosis 
(LAAS); (2) Cardio-Embolic Infarct (CEI); (3) LACunar infarct 
(LAC); (4) stroke of Other Determined Etiology (ODE); (5) stroke 
of UnDetermined Etiology (UDE). We enrolled 107 patients with 
acute ischemic stroke and 102 control subjects matched for age, 
sex, cardiovascular risk factors and previous cardiovascular mor-
bidity.  
 According to the TOAST criteria, the etiology of stroke was 
large-artery atherosclerosis (LAAS) in 41 (38. 31%) patients, cardi-
oembolism (CEI) in 31 (28. 97%) patients, lacunar stroke in 32 (29. 
92%) patients whereas 3 (2. 80%) subjects were classified as ODE. 
After adjustment for glucose, cholesterol and triglyceride blood 
levels stroke patients, compared to subjects without acute ischemic 
stroke, showed a higher mean Augmentation Index (Aix) (103±3. 
5% vs. 99±4. 6%) and PWV (11. 8±3. 3 m/s vs10. 02±2. 29 m/s). 
After adjustment for SBP/DBP, MAP, Diabetes, Hypertension, 
Hypercholesterolaemia, Previous TIA, Previous stroke, Glucose 
blood levels, Total cholesterol blood levels LDL cholesterol, 
Triglyceride blood levels, Microalbuminuria, Augmentation Index 
(Aix) and PWV values in lacunar subjects (112±5. 5%; 11. 98±2. 
445 m/s) were significantly higher compared to values observed in 
LAAS (108±3. 5%; 5. 80±0. 445 m/s), CEI (104±3. 5%; 10. 40±2. 
445 m/s) and ODE (105±3. 5%; 11. 48±1. 345 m/s) subtypes.  
 Relationship between PWV and clinical and laboratory vari-
ables in stroke patients PWV was significantly and positively re-
lated with body mass index (BMI) (r = 0. 416; p < 0. 001), age (r = 
0. 403; p < 0. 001), SBP (0. 493; p < 0. 001), mean arterial pressure 
(MAP) (r = 0. 579; p < 0. 001), hypertension (r = 0. 403; p < 0. 
001), diabetes (r = 0. 397; p < 0. 05), previous transient ischemic 
attack (TIA) (r = 0. 319; p = 0. 045), previous stroke (r = 0. 380; p 
< 0. 001), glucose blood levels (r = 0. 307; p = 0. 039), low density 
lipoprotein (LDL) cholesterol plasma levels (r = 0. 355; p < <0. 
001), total cholesterol plasma levels (r = 0. 323; p = 0. 041), 
triglyceride plasma levels (r = 0. 318; p < 0. 001), coronary artery 
disease (CAD) (r = 0. 380; p < 0. 001), microalbuminuria (r = 0. 
393; p < 0. 001), carotid plaque (r = 0. 380; p < 0. 001), left ven-
tricular hypertrophy (LVH) (r = 0. 480; p < 0. 001), previous brain 
infarct at neuroimage (r = 0. 390; p = <0. 001), white matter hyper-
intensity lesions (WMHLs) (r = 0. 340; p < 0. 05) . Relationship 
between Aix and clinical and laboratory variables in stroke patients 
The Aix was significantly related to BMI (r = 0. 40; p < 0. 001), 
Age (r = 0. 41; p < 0. 001), SBP (r = 0. 43; p < 0. 001), diastolic 
blood pressure (DBP) (r = 0. 43; p < 0. 001), MAP (r = 0. 427; p < 
0. 001), hypertension (r = 0. 431; p < 0. 001), microalbuminuria (r = 
0. 305; p < 0. 001), carotid plaque (0. 378; p < 0. 001), LVH (r = 0. 
399; p < 0. 05), white matter hyperintensity lesions WMHLs (r = 
00. 310; p = 0. 038).  
 Our study shows that patients with ischemic stroke have higher 
value of indexes of arterial stiffness in relation to age, sex and car-
diovascular risk factor compared to control subjects and that a sig-
nificant relationship exists between these indexes and some clinical 
and laboratory variables.  
 Furthermore, at intergroup analysis our findings show a signifi-
cant difference among TOAST diagnostic subtype with regard to 
arterial stiffness indexes. Wereport that subjects with lacunar sub-
type show higher values of PWV and Aix compared to LAAS and 
CEI subtypes. Few studies examined the relationship between arte-
rial stiffness indexes and systemic inflammation markers such as 
pro-inflammatory cytokines [161], whereas no study has evaluated 
the relationship between these indexes and immune-inflam-matory 
markers in patients with an acute cardiovascular or cerebrovascular 
event. Only one study [162] indirectly evaluated this relationship 
and only with regard to erythrocyte sedimentation rate (ESR).  
 On this basis the aim of another study by our group [163] was 
to evaluate the relationship between arterial stiffness and cytokine, 
selectin, adhesion molecule and Von Willebrand factor plasma 
levels in subjects with acute ischemic stroke.  
We enrolled all consecutive patients with a diagnosis of acute 
ischemic stroke admitted to the Internal Medicine Department at the 
University of Palermo between November 2006 and January 2008, 
and hospitalized control patients without a diagnosis of acute 
ischemic stroke. Control subjects were patients admitted, in the 
same period, to our Internal Medicine Department for any cause 
other than acute cardiovascular and cerebrovascular events.  
 Carotid-femoral PWV was measured in the supine position 
using the automatic device (SphygmoCor version 7. 1) that meas-
ured the time delay between the rapid upstroke of the carotid and 
femoral artery pulse waves. The distance between the 2 arterial 
points was measured on the surface of the body using a tape meas-
ure. PWV was calculated as the distance traveled by the arterial 
pulse wave (meters) divided by the time delay between the 2 arte-
rial points (seconds), thus expressed as meters per second.  
 Applanation tonometry was used to record radial artery pressure 
waveform continuously, and mean values of 2 screens of pulse 
waves of good quality were used for analysis. On the basis of the 
collected data, an averaged radial pressure waveform was generated 
and a corresponding aortic pressure waveform and BP calculated by 
the validated transfer function (SphygmoCor version 7. 1). The 
aortic pressure waveform was used to calculate the Aix (difference 
in height between the first and second systolic peaks expressed as a 
percentage of pulse pressure (PP).  
 We evaluated plasma levels of C-reactive protein (CRP), Inter-
leukin-1beta (IL-1), tumor necrosis factor-alpha (TNF-) , Inter-
leukin-6 (IL-6) and Interleukin-10 (IL-10), E-selectin, P-selectin, 
intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion 
molecule-1 (VCAM-1), as markers of immune-inflammatory acti-
vation, von Willebrand Factor (vWF) plasma levels as a marker of 
endothelial dysfunction, tissue plasminogen activator (TPA) and 
plasminogen activator inhibitor-1 (PAI-1) as marker of thrombotic/ 
fibrinolytic pathway.  
 We enrolled 107 patients with acute ischemic stroke and 107 
control subjects matched for age, sex, cardiovascular risk factors 
and previous cardiovascular morbidity.  
 According to the TOAST criteria, the etiology of stroke was 
large-artery atherosclerosis (LAAS) in 41 (38. 31%) patients, cardi-
oembolism (CEI) in 31 (28. 97%) patients, lacunar stroke in 32 (29. 
92%) patients whereas 3 (2. 80 %) subjects were classified as ODE. 
There was a significant positive relationship, corrected for age, and 
gender, between PWV and CRP (r=0. 36; P<0. 001), TNF- (r=0. 
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42; P<0. 001), IL1 (r=0. 35; P<0. 001), VWF (r=0. 46; P<0. 001), 
and IL-6 (r=0. 21; P<0. 05).  
The Aix was significantly related, after correction for age and gen-
der, to VWF (r=0. 38; P<0. 0001), but not to CRP (r=0. 09; P=0. 
37), IL-6 (r=0. 18; P<0. 08), or TNF- (r=0. 14; P<0. 15) levels.  
 Among Lacunar subtype PWV, after correction for age and 
gender, was significantly and positively related to CRP, IL-1 , IL-
6, TNF- and vWF.  
 In subjects with stroke classified as LAAS, PWV was signifi-
cantly and positively related to CRP, IL-1, IL-6, TNF- but not 
with vWF.  
 In CEI subtype, PWV was significantly and positively related to 
TNF- and vWF but not with CRP, IL-6, IL-1. Among Lacunar 
and CEI subtype Aix was positively and significantly related, after 
correction for age and gender, only to vWF; in LAAS subgroup this 
relationship was significantly weaker and only close to statistical 
significance.  
 The main our findings were that patients with acute ischemic 
stroke had both increased inflammatory markers and arterial stiff-
ness markers compared to control subjects without acute ischemic 
stroke.  
 This is the first study to show in patients with acute ischemic 
stroke that circulating levels of some immune-inflammatory mark-
ers such as CRP, IL-6, IL-1 , TNF- and VWF are related to PWV 
and wave reflection. Our findings show that both aortic stiffness 
and wave reflection are related to the degree of systemic inflamma-
tion in stroke subjects, suggesting that circulating inflammation 
mediators such as CRP and some pro-inflammatory cytokines can 
influence the stiffness of vessels distant to those involved in the 
disease process itself. An immune-inflammatory cascade occurs 
after an acute ischemic stroke [164, 165] so on this basis cytokine 
levels that we reported and measured 72 hr from symptom onset 
express an acute rise of these inflammatory markers.  
 On this basis it is possible that observed differences with regard 
to the relationship between arterial stiffness indexes and inflamma-
tory markers could be related to differences in immune-
inflammatory activation of the acute phase of each TOAST diag-
nostic subtype.  
 Our finding concerning some differences in the observed corre-
lation between immune-inflammatory markers and arterial stiffness 
indexes in relation to each TOAST subtype of stroke might also 
indicate a different degree of vascular anatomy impairment or a 
different distribution of certain risk factors already reported as re-
lated to the inflammation markers, such as hypertension and diabe-
tes. In fact our patients with lacunar stroke, in which both CRP, IL-
6, IL-1 , TNF- and vWF are related to PWV, have an higher 
frequency of both hypertension and diabetes and this finding allow 
it to represent, in some ways the prototype of the acute cerebrovas-
cular event in diabetic or hypertensive subjects. Furthermore the 
molecular events associated with remodelling of the large and 
medium to small arteries also have been well characterized and 
involve the combinatorial influences of adhesion molecules, 
integrins, metallo-proteinases, the renin-angiotensin axis, and 
inflammation on the cellular constituents (endothelial cells , 
vascular smooth cells, fibroblasts, and matrix components) of 
the vasculature [166, 167].  
 Biomarkers of inflammation like CRP, interleukin-6, and tumor 
necrosis factor- have been associated positively with both indirect 
(e. g. brachial artery pulse pressure) [167, 168] and direct measures 
of arterial stiffness in previous studies in apparently healthy indi-
viduals, [169] in specific patient groups (e. g. patients with hyper-
tension) [170], and in community-based samples [171, 172, 173]. 
Most of these studies had modest sample sizes, but no study evalu-
ated the relationship between stiffness indexes and immune-
inflammatory markers in patients with acute ischemic stroke or 
other acute cardiovascular event, so our findings appear novel. Pre-
vious studies have shown that exogenously administered cytokines 
(specifically IL-1) cause a NO-mediated basal vasodilation in 
human veins by inducing the constitutively expressed endothelial 
nitric oxide (NO)-synthase [174]. Nevertheless in acute ischemic 
stroke excitotoxic or ischemic conditions excessively activate 
nNOS, resulting in concentrations of NO that are toxic to surround-
ing
 
neurons [175]. But what are extra-cerebral large artery levels of 
NO in ischemic stroke subjects? No study to our knowledge ana-
lyzed this issue 
 Another possible limitation because of technical limitations 
with regard of Aix evaluation is that we recruited in patients with 
cardioembolic subtype of stroke patients subjects with atrial fibril-
lation. However, other studies that have assessed the markers of 
arterial stiffness in patients with atrial fibrillation, have evaluated 
both PWV and Aix [176, 177].  
 Maybe an acute NO depletion role is not directly presumable to 
explain an acute rise in arterial stiffness in acute stroke patients. For 
this series of limitations whether our findings can be extended to a 
chronic situation is a matter of discussion that future studies should 
be clarify evaluating arterial stiffness indexes change in subjects at 
cerebrovascular risk before and after an acute ischemic cerebrovas-
cular event.  
 The arterial changes have a multitude of potential intercon-
nected causes including endothelial dysfunction, oxidative stress, 
inflammation, atherosclerosis and vascular calcification. The role 
and contribution of the biochemical changes to arterial stiffness in 
the acute phase ischemic stroke is not known, but it’s likely that 
immune-inflammatory activation, acute hyperglycemia, endothelial 
disfunction and other toxic effects could be responsible of a acute 
increase of arterial stiffness after ischemic stroke. In conclusion we 
reported that both aortic stiffness and wave reflection are related to 
the degree of systemic inflammation in stroke subjects, showing a 
significant relationship between immuno-inflammatory marker and 
PWV in LAAS and lacunar subtype of stroke and suggesting that 
circulating inflammation mediators after acute ischemic stroke can 
influence the stiffness of vessels distant to those involved in the 
disease process itself.  
 Previous studies of infection and stroke have found that most 
infections among stroke cases were located in the respiratory tract. 
[178-180] A case-control study in Germany [181] found that recent 
infection was associated with cardioembolic stroke. In the subgroup 
with febrile infection (19 of 197 strokes), almost half the patients (9 
of 19) suffered from cardioembolic stroke. Small-vessel disease 
was diagnosed as the cause of cerebral ischemia only in patients 
without recent infection. Another study by the same researchers17 
also found recent infection significantly increased the risk of cere-
brovascular ischemia from cardioembolism and tended to elevate 
the risk for arterioarterial embolism.  
 Infections may induce thrombosis and brain infarction by sev-
eral mechanisms. Some mechanisms link infections with large-
artery atherogenesis. Other mechanisms suggest a prothrombotic 
state. Infection and inflammation cause many systemic effects, 
including changes in lipid metabolism, platelet aggregation, lysis, 
blood coagulation, alterations in endothelial function, spasms in 
vascular smooth muscle, atheroma instability, and subsequent 
plaque rupture. Compared with stroke patients without infection, 
those with infection were found to have increased fibrin D-dimer 
concentrations and anticardiolipin antibody titers [182]. Likewise, 
infection-associated stroke patients had lower levels of activated 
protein C and ratios of active tissue plasminogen activator to plas-
minogen activator inhibitor-1 and elevations in C4bp antigen levels 
than noninfection stroke cases or controls [183].  
 Although prior studies have demonstrated that 25% to 35% of 
stroke patients have had a recent infection, the role of infection as a 
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risk factor remains unclear. Our aim was to characterize the effect 
of infectious/inflammatory syndromes on stroke risk.  
 Some authors performed [184] a case-control and crossover 
analyses of 233 cases and 363 controls aged 21 to 89 years per-
formed. Cases were patients hospitalized with a first ischemic 
stroke at a Los Angeles, California, medical center. Controls were 
outpatients in the hypertension, diabetes, and general medical clin-
ics. All subjects were administered a neurological examination, an 
infection/inflammation (I/I) examination, and an interview to elicit 
recent I/I history at baseline (within several days of stroke onset) 
and again approximately 2 months later. Three physicians classified 
subjects by the presence or absence of I/I within 1 month of the 
index dates, based on findings of the I/I examination, the interview 
report, and laboratory results.  
 Infections, either total or specific, were not found more fre-
quently in cases than controls. However, patients with a recent res-
piratory tract infection suffered more often from large-vessel 
atherothromboembolic or cardioembolic stroke than did patients 
without infection (48% vs 24%, P=0. 07). The age- and sex-
adjusted relative risk estimate for these subtypes was 1. 75 (95% 
CI, 0. 86 to 3. 55). The risk was notably high for those without 
stroke risk factors: 4. 15 (95% CI, 1. 22 to 14. 1) for normotensives, 
2. 71 (95% CI, 1. 04 to 7. 06) for nondiabetics, and 1. 74 (95% CI, 
0. 74 to 4. 07) for nonsmokers. Patients with a recent respiratory 
infection also had a more severe neurological deficit on admission 
than those without infection (P=0. 05).  
 Our results suggest that respiratory tract infection may act as a 
trigger and increase the risk of large-vessel and/or cardioembolic 
ischemic stroke, especially in those without vascular risk factors 
Furthermore, platelet activation and its interaction with leukocytes 
are important in the pathophysiology of ischemic stroke. This study 
aimed to evaluate the value of platelet activation and platelet-
leukocyte interaction in different subtypes of acute, non-cardio-
embolic ischemic stroke.  
 In a study by [185] fifty-four patients with acute, non-cardio-
embolic ischemic stroke, including 32 small-vessel and 22 large-
vessel diseases, were evaluated. Platelet activation markers 
(CD62P, CD63, and CD40L) and platelet-leukocyte interaction 
were measured by flow cytometry at different time points (<48 
hours and Days 7, 30, and 90 post-ischemic stroke). Markers were 
also evaluated in 28 other stroke patients in the convalescent stage 
(3 to 9 months after acute stroke) and in 28 control subjects. Pa-
tients with ischemic stroke had significantly increased circulating 
CD62P, CD63, platelet-monocyte interaction, and platelet-
lymphocyte interaction in the acute stage compared with the conva-
lescent stage and control groups. Levels of CD62P and CD63 were 
significantly higher in the large-vessel disease group than in the 
small-vessel disease group, and differences in CD62P were signifi-
cant even at one month. The CD40L level in the poor outcome 
group was significantly higher than that in the good outcome group. 
Stroke patients with diabetes mellitus and large-vessel disease were 
associated with poor outcome. Patients with large-vessel cerebral 
infarction elicit higher platelet activation and platelet-leukocyte 
interaction compared to small-vessel infarction. Further large scale 
trials are warranted to evaluate the relationship between platelet 
activation markers and outcome in stroke patients under different 
anti-platelet therapies, and to clarify optimal treatment.  
 Activation of endothelial cells and platelets is an important 
mediator of atherothrombosis. Markers of endothelial cell and 
platelet activation such as soluble adhesion molecules can be meas-
ured in plasma. Cherian et al. [186] hypothesized that patients with 
acute ischemic stroke would have increased blood concentrations of 
soluble E-selectin and von Willebrand factor (vWF), primarily re-
flecting activation of endothelial cells, and increased concentrations 
of soluble P-selectin and platelet-derived microvesicles (PDM), 
primarily reflecting activation of platelets, compared with healthy 
controls. We also hypothesized that these markers would be differ-
entially elevated in ischemic stroke caused by large- and small-
artery atherothrombosis compared with cardiogenic embolism.  
 We conducted a case-control study of 200 hospital-referred 
cases of first-ever ischemic stroke and 205 randomly selected 
community controls stratified by age, sex, and postal code. Using 
established criteria, we classified cases of stroke by etiological 
subtype in a blinded fashion. The prevalence of vascular risk factors 
and blood concentrations of E-selectin, P-selectin, vWF antigen, 
and PDM were determined in stroke cases within 7 days and at 3 to 
6 months after stroke and in controls.  
 Mean blood concentrations of soluble E-selectin, P-selectin, 
and PDM within 7 days of stroke onset were all significantly higher 
in cases compared with controls. At 3 to 6 months after stroke, the 
mean blood concentrations of E-selectin and P-selectin fell signifi-
cantly below that of controls, and PDM concentrations remained 
elevated. There was a strong, graded, and independent (of age, sex, 
and vascular risk factors) association between increasing blood 
concentrations of E-selectin during the acute phase and all etiologi-
cal subtypes of ischemic stroke, particularly ischemic stroke caused 
by large-artery atherothrombosis. There was also a significant, 
graded, and independent association between increasing blood con-
centrations of vWF during the acute phase and ischemic stroke 
caused by large-artery atherothrombosis.  
 On this basis these authors demonstrated significant associa-
tions between acute elevation of blood markers of endothelial cell 
and platelet activation and ischemic stroke and between acute ele-
vation of blood markers of endothelial cell activation and ischemic 
stroke caused by large-artery atherothrombosis. Persistent elevated 
blood concentrations of PDM may be a marker of increased risk of 
ischemic stroke.  
 Moreover, The CD40 ligand (CD40L) on platelets may be a 
critical factor to develop the acute vascular events from atheroma. 
Cha et al. [187] to determine the role of CD40L on platelets in athe-
rosclerotic ischemic stroke, we serially measured the expressions of 
CD63, P-selectin and CD40L on platelets in patients with athero-
sclerotic ischemic stroke (n = 25) and compared them with those in 
patients with asymptomatic carotid stenosis (n = 20) and in normal 
subjects (n = 24).  
 The expressions of CD63 and P-selectin on platelets were sig-
nificantly higher in patients with atherosclerotic ischemic stroke (n 
= 25) than in normal subjects (n = 24). The extents of surface ex-
pressions of CD63 and P-selectin on platelets showed no significant 
differences between atherosclerotic ischemic stroke and asympto-
matic carotid stenosis. However, the CD40L expression on platelets 
was significantly higher in atherosclerotic ischemic stroke when 
compared to that in asymptomatic carotid stenosis.  
 In this study among the population with large artery atheroscle-
rosis, the patients with symptomatic ischemic events showed a sig-
nificantly elevated expression of CD40L on platelets compared to 
those without ischemic events. Therefore, the upregulation of 
CD40L on platelets may be a specific marker of platelet activation 
to provoke ischemic stroke from large artery atherosclerosis.  
 The sites of platelet activation in ischemic stroke are still un-
clear because previous reports have not identified them and various 
factors accompanied by stroke can activate platelets. We therefore 
examined the sites of platelet activation in patients with various 
types of ischemic stroke.  
 Iwamoto et al. [188] calculated The ratio of the plasma concen-
tration of beta-thromboglobulin (BTG) in the internal jugular vein 
to that in the antecubital vein (BTG-B) as an indicator of platelet 
activation in the cerebral circulation. Plasma BTG concentration 
was determined in 75 control subjects and in 186 patients with vari-
ous subtypes of ischemic stroke including lacunar, atherothrom-
botic, and cardioembolic strokes, transient ischemic attacks, and 
Binswanger's disease. The BTG ratio was evaluated with regard to 
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subtype of stroke, time of blood sampling, size of infarct, presence 
of vascular lesions, and the effect of ticlopidine administration. The 
mean BTG ratio was increased even in the chronic phase of most 
subtypes of stroke with the exception of cardioembolic stroke, 
which exhibited a persistent elevation of BTG-B concentrations. 
Patients with Binswanger's disease showed a significant and fre-
quent elevation of BTG ratio. High BTG ratios occurred in cases 
with vascular lesions observed on cerebral angiography. There was 
no correlation between the BTG ratio and infarct size. Use of ti-
clopidine was partially associated with a lower BTG ratio.  
 The findings of this study show that platelets were activated in 
the cerebral circulation of patients with stroke even in the chronic 
phase, which suggests the development of underlying vascular le-
sions and of thrombogenesis with or without infarction. Platelets 
were activated mainly within the heart in cases of cardioembolic 
stroke. An enhanced release reaction secondary to platelet activa-
tion was often seen in patients with Binswanger's disease, which 
indicates that its pathophysiology differs from that of other sub-
types of stroke. In a study by Oberheiden et al. [189] the role of 
platelets and cellular coagulation activation in cerebral small-vessel 
disease (cSVD) was assessed. In 24 patients with cSVD but without 
established large-vessel disease, whole blood samples were ob-
tained. Patients were divided into three subgroups (according to 
extent of cSVD based on morphological magnetic resonance imag-
ing criteria. Surface expression of CD40L and CD62P on platelets, 
tissue-factor exposition on monocytes and platelet-monocyte ag-
gregates were measured with flow cytometry. Plasma levels of 
soluble CD40L, interleukin (IL)-6 and IL-7 were assessed by 
ELISA. Patients with cSVD show a significantly elevated expres-
sion of platelet CD40L (P < 0. 001) and CD62P (P < 0. 023), sig-
nificantly elevated amounts of platelet-monocyte aggregates (P < 0. 
004), a significantly enhanced tissue-factor exposition on mono-
cytes (P < 0. 019) and significantly lower plasma levels of IL-7 
compared to 10 healthy controls. However, this platelet and mono-
cyte activation did not correlate with the severity of cSVD. Patients 
with cSVD show an up-regulation of the platelet CD40L and 
CD62P system and an activation of cellular coagulation which 
might contribute to the initiation and progression of cSVD.  
 Nevertheless, it remains uncertain whether platelet activation in 
ischemic stroke is contributory or secondary to brain ischemia. The 
efficacy of aspirin (ASA) in stroke prevention suggests that platelet 
activation contributes to the occurrence of stroke. On the other 
hand, platelet activation may be simply a generalized consequence 
of cerebral ischemic damage. To examine this issue, in a study by 
Shah et al. [188] plasma levels of the platelet specific proteins beta-
thromboglobulin (beta-TG) and platelet factor 4 (PF4) were meas-
ured in fifty-eight patients with various defined types of acute 
ischemic strokes. beta-TG was a broader indicator of platelet acti-
vation than PF4. Compared with an age-matched control group, 
thromboembolic and cardioembolic stroke patients had significantly 
elevated beta-TG levels (p less than 0. 001). Also, beta-TG levels in 
these stroke categories were significantly higher in samples drawn 
within the first week after the event than in those drawn later (p less 
than 0. 001). In contrast, beta-TG levels in lacunar stroke patients 
and in most TIA patients were normal. beta-TG levels did not cor-
relate with the volume of cerebral infarction as measured by plani-
metry from CT scans. Moreover, beta-TG levels in patients on 
chronic ASA therapy at the time of stroke did not differ from those 
in patients of the same diagnostic categories not taking aspirin. 
These data indicate that platelet activation may be important in 
some, but not all, subtypes of ischemic stroke and that platelet acti-
vation can occur in stroke even though the platelet cyclooxygenase 
pathway is suppressed.  
 Previous studies have shown evidence of inflammatory activa-
tion and endothelial dysfunction in individuals with lacunar infarc-
tion and WML. More recently, higher CRP levels have been associ-
ated with presence and progression of WML in a population-based 
sample of nondemented elderly Europeans. A significant associa-
tion between higher CRP and IL6 levels and presence of silent BI 
was also reported in Japanese individuals. Although these studies 
provide support for a link between inflammatory markers and small 
vessel disease pathogenesis, it is yet unclear whether small vessel 
disease of the brain is directly and causally influenced by increased 
levels of inflammatory markers, or itself induces increased synthe-
sis of inflammatory molecules, or both.  
 To further investigate the relationship between molecular mark-
ers of inflammation and small vessel disease of the brain, Fornage 
et al. [190] conducted an association study of the sequence varia-
tion in 2 inflammation genes, CRP and IL6, with presence of WML 
and BI among elderly participants in the Cardiovascular Health 
Study (CHS). Tag single nucleotide polymorphisms (SNPs) in the 
CRP and IL6 genes were selected from the SeattleSNPs database. 
In cross-sectional analyses, logistic regression models adjusting for 
known cardiovascular disease risk factors were constructed to as-
sess the associations of plasma CRP and IL6 levels and common 
CRP and IL6 gene haplotypes with presence of WML or BI in 
Blacks (n=532) and Whites (n=2905).  
 Plasma IL6 and CRP levels were associated with presence of 
WML and BI in both races. In Whites, common haplotypes of the 
IL6 gene were significantly associated with WML and BI. The 
common haplotype tagged by the -174G/C promoter polymorphism 
was associated with an increased risk of WML (OR=1. 14; 95% CI: 
[1. 02; 1. 28]). The common haplotype tagged by the -572G/C pro-
moter polymorphism was associated with an increased risk of BI 
(OR=1. 57; 95% CI: [1. 15; 2. 14]). Significant associations were 
lacking for WML or BI with IL6 gene variation in Blacks, or with 
CRP gene variation in either race. This study provides evidence of a 
genetic basis underlying the relationship between plasma biomark-
ers of inflammation and small vessel disease of the brain. Further 
studies to elucidate the specific role of IL6 in disease pathogenesis 
are warranted 
DISCUSSION  
 Within the broad large category of brain ischemia, subtypes 
also vary dramatically in cause: from systemic hypoperfusion to 
atherosclerotic large artery disease to penetrating artery disease to 
dissection to emboli arising from the heart valves or atria, to emboli 
arising from the aorta to paradoxical emboli to occlusion of cerebral 
and dural sinus vein to hypercoagulability. These subtypes are as 
different as grapes and watermelons: two substances contained 
within the large category of fruits [191]. 
 Nevertheless evidence is mounting suggesting that chronic in-
flammation contributes to the development and consequences of 
cardiovascular disease. Numerous prospective studies have shown 
associations of serum levels of biomarkers of inflammation such as 
C-reactive protein (CRP), interleukin 6 (IL6), and fibrinogen with 
myocardial infarction, stroke, cardiovascular death, and peripheral 
arterial disease.  
 During the course of brain ischemia, inflammatory mechanisms 
both intrinsic to brain as well as blood are among the important 
mediators of focal cerebral injury. With the onset of focal brain 
ischemia, microglia become activated within the penumbra and 
thereby facilitate further local neuronal injury via pathways that 
include poly(ADP-ribose) polymerase-1 activation and activation of 
multiple MMPs. The activation of MMPs disrupts the blood-brain 
barrier, alters microvascular endothelial function and impairs the 
functional integrity of the neurovascular unit. These events promote 
the entry of peripheral leukocytes into brain and expose “protected” 
cerebral elements to peripheral immune surveillance systems.  
 On this basis The onset of cerebral ischaemia triggers a cascade 
of proinflammatory molecular and cellular events. Clinical studies 
suggest that the strength of this acute response is important in early 
and late clinical outcomes, early clinical worsening, and extent of 
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brain damage. Variables that are predictors of adverse stroke out-
come include erythrocyte sedimentation rate, and levels of C-
reactive protein (CRP), interleukin-6, tumour necrosis factor- and 
intercellular adhesion molecule-1. Current data indicate that in-
flammation serves to fuel atherosclerosis and can act as the link 
between atherosclerosis and atherothrombosis. Growing evidence 
indicates that platelets act as prominent players in the inflammatory 
component of these disease processes. Thus, upon activation, plate-
lets release a series of cytokines and growth factors and express 
CD40 ligand, which interacts with the CD40 receptor on other ma-
jor cell types involved in atherosclerosis/atherothrombosis. In 
healthy volunteers. Of a range of potential inflammatory biomark-
ers that have been reported in the literature, the best studied are 
CRP, TNF-. IL-6, IL-1 , and other cytokines, adhesion molecules 
and integrins. Such biomarkers may have clinical utility for refined 
identification of patients at high risk for atherothrombosis in differ-
ent arterial beds and for monitoring of therapeutic agents in clinical 
trials. If different subtypes of ischemic stroke differ in pathophysi-
ology, clinical manifestations and possible extension of neuronal 
damage similar then different could be the type and degree of im-
munoinflammatory activation of each subtype diagnostic? Several 
studies also conducted by our group have been addressed to try to 
answer to this question showing that cardioembolic and atheroscle-
rotic strokes in comparison with lacunar strokes show the highest 
degree of immunoinflammatory activation of the acute phase.  
These differences in immunoinflammatory activation may probably 
explain differences in acute neurological deficit and disability grade 
at follow-up in relation of each TOAST subtype of ischemic stroke 
and effects of inflammation on surrogate vascular endpoints such as 
arterial stiffness indexes.  
 Maybe an acute NO depletion role is not directly presumable to 
explain an acute rise in arterial stiffness in acute stroke patients. For 
this series of limitations whether our findings can be extended to a 
chronic situation is a matter of discussion that future studies should 
be clarify evaluating arterial stiffness indexes change in subjects at 
cerebrovascular risk before and after an acute ischemic cerebrovas-
cular event.  
 The arterial changes have a multitude of potential intercon-
nected causes including endothelial dysfunction, oxidative stress, 
inflammation, atherosclerosis and vascular calcification. The role 
and contribution of the biochemical changes to arterial stiffness in 
the acute phase ischemic stroke is not known, but it’s likely that 
immune-inflammatory activation, acute hyperglycemia, endothelial 
disfunction and other toxic effects could be responsible of a acute 
increase of arterial stiffness after ischemic stroke.  
 This finding may have potential therapeutic applications aimed 
to reducing arterial stiffness by interfering with these biochemical 
changes of acute phase after ischemic stroke by means neuroprotec-
tive agents like anti-inflammatory or anti-oxidizing agents or car-
diovascular drug with potential pleiotropic actions such as statins, 
The inflammatory response in acute stroke continues to present a 
number of inviting therapeutic targets, but evidence of the inde-
pendent contribution of inflammation over and above other risk 
factors is not yet ideal in any of the areas discussed. Large-scale 
studies of primary stroke risk that involve high-quality phenotyping 
of incident stroke are required. Assumptions that risk models de-
rived from coronary heart disease apply to ischaemic stroke are 
likely to highlight inconsistencies due to the multiple underlying 
disorders that cause stroke. Acute inflammation is clearly impli-
cated in atherosclerotic plaque instability, and in this specific sub-
group of patients, imaging markers of localized inflammation may 
be valuable in risk stratification and clinical management. A need 
exists, however, for more practical techniques to achieve this.  
 Although initial brain inflammation can contribute to the degree 
of brain damage following injury, longer-term anti-inflammatory 
interventions to limit the degree of damage might interfere with 
nervous regeneration and recovery, therefore not fully understood 
to date appear the issue of the immune system that is not simply 
deleterious in the context of neurological damage after brain ische-
mia, Targeting inflammatory mediators such as cytokines, adhesion 
molecules, Toll receptors, neutrophils, macrophages and leukocyte 
provide opportunities to intervene with novel therapeutics in stroke. 
Indeed significant data demonstrate that brain inflammatory re-
sponse is a contributing factor to evolving brain injury that occur 
following focal stroke. Along this line of research and therapeutic 
approach. Nevertheless, to our knowledge so far no study has ex-
amined differences in the efficacy of anti-inflammatory therapy in 
patients with ischemic stroke in relation to the different subtype 
TOAST. 
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